Conflict between the medical patents and the right to health by Kolk, Karlis
UNIVERSITY OF TARTU 
SCHOOL OF LAW 
Department of International Law and Human Rights 
 
 
 
 
 
 
 
 
Karlis Kolk 
 
CONFLICT BETWEEN THE MEDICAL PATENTS AND THE RIGHT TO HEALTH 
Master’s Thesis 
 
 
 
 
 
 
 
 
Supervisor 
PhD Aleksei Kelli 
 
 
 
 
 
 
 
 
Tallinn 
2018  
2 
 
Contents 
 
Introduction ................................................................................................................................ 3 
1 Intellectual Property Covering Pharmaceuticals ................................................................ 8 
1.1 Importance of Patent Protection ............................................................................. 11 
1.1.1 Stage of Research and Development .................................................................. 13 
1.1.2 Most Crucial Phase of Innovation ...................................................................... 13 
1.2 European Union Practice and Approach ................................................................ 15 
1.2.1 European Union Biotech Directive..................................................................... 17 
1.2.2 TRIPS Application within the EU ...................................................................... 18 
2 Human Right to Health ..................................................................................................... 21 
2.1 The Basis: Universal Declaration of Human Rights .............................................. 21 
2.1.1 Lawfully Binding Covenant ............................................................................... 22 
2.1.2 Essence of Right to Health ................................................................................. 24 
2.2 State Obligation to Uphold Public Health .............................................................. 26 
2.3 European Union Approach ..................................................................................... 28 
2.4 Conflict with Patent Law........................................................................................ 29 
3 Means to Resolve the Conflict.......................................................................................... 35 
3.1 Compulsory Licensing and Doha Declaration ....................................................... 40 
3.1.1 Integrating 2003 Decision into TRIPS ............................................................... 43 
3.1.2 About the Amendment ....................................................................................... 45 
3.2 Integration of TRIPS in the EU .............................................................................. 48 
3.2.1 EU Regulation to Avoid Trade Diversion of Key Medicines ............................ 48 
3.2.2 EU Regulation on Compulsory Licensing .......................................................... 51 
Conclusion ................................................................................................................................ 57 
Abbreviations ........................................................................................................................... 63 
Bibliography ............................................................................................................................. 64 
 
  
3 
 
Introduction 
 
The clash between the human right to health and medical patents is an issue that has become a 
subject of great concern in the international law.1 The Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS Agreement)2 regulates the patents for medicines which has 
been considered as a conflicting side to human rights, especially to right to health as enforced 
by the International Covenant on Economic, Social and Cultural Rights (ICESCR)3. There are 
tensions between the two regulations, thus it is important to find a balance between them and 
also solutions to the possible problems that the study might reveal. 
 
The question is examined from the perspective of the issue of access to affordable medicines in 
developing countries focusing on the right to health as set out in the ICESCR and patent 
standards (and flexibilities) as required by the TRIPS Agreement. In the strict sense, there is no 
conflict between the right to health and patents. ICESCR and TRIPS do not contain mutually 
exclusive obligations. Yet, it is shown that tension between the two does exist. There are a 
number of ways in which such tension can be resolved. The United Nations (UN) Sub-
Commission for the Promotion and Protection of Human Rights has contended that human 
rights should enjoy primacy over patents, yet there is no evidence to suggest that the right to 
health and/or access to essential medicines are considered prioritised norms under international 
law. The World Trade Organization (WTO) disagrees and views Intellectual Property Rights 
(IPRs) and human rights as complementary. In international law there is a strong presumption 
against conflict. In line with the principle of systemic integration a good faith interpretation of 
the relevant WTO and human rights provisions should lead to a reading of TRIPS’ obligations 
which is coherent with human rights law. However, this balancing act must also take place at 
the domestic level and the success of such a coexistence approach, namely whether 
(developing) states are able to strike a balance between access to medicines and patent 
protection, will depend much on the actual implementation and interpretation by states. 
Consequently, some examples of state practice regarding the interpretation and implementation 
of TRIPS in light of the right to health are highlighted. 
 
 
 
                                                 
1 P. Cullet. Patents and medicines: the relationship between TRIPS and the human right to health. – 79 
International Affairs 2003(1), pp. 139-160. 
2 Trade-Related Aspects of Intellectual Property Rights. Marrakesh 15.04.1994, e.i.f. 01.01.1995. 
3 International Covenant on Civil and Political Rights. New York 16.12.1966, e.i.f. 23.03.1976. 
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Ha-Joon Chang stated that: 
“Patent monopoly creates a lot of problems. It allows the patentee to charge the maximum to 
consumers. This may not be a problem if the patented product is a luxury item, like parts that 
go into a smartphone, but can violate basic human rights if it involves things such as life-saving 
drugs.”4 
 
The hypothesis of this study is that there is a conflict between the medical patents and the right 
to health, because medical patents are in some cases greatly restricting the right to health. 
However, there is also a solution to this conflict. 
 
The research questions are as follows: 
• Is there a balance between the medical patents and the right to health? 
• If there is no balance between the medical patents and the right to health, then how to 
balance them? 
• Why is it important that there is a balance between the medical patents and the right to 
health? 
• Who is responsible for finding a balance between the medical patents and the right to 
health? 
• What is the relevant legislation in connection with the subject? 
• What is the common practice among States in connection with medical patents and the 
right to health? 
• Where to strike the balance? 
 
This study will benefit the society as a whole because if there is a balance between the medical 
patents and the right to health then the medicines will be made easily available for the public 
and also the interests of the pharmaceuticals companies are protected. It is self-evident why the 
availability of different medicines benefits the society. However, protecting the interests of 
pharmaceutical enterprises matters as well. If pharmaceuticals companies do not get rewarded 
for their efforts in producing and inventing medicines then they might lose interest in producing 
any more medicines which will impede the scientific progress of medicines. 
 
                                                 
4 R. Aggarwal and R. Kaur. Patent Law and Intellectual Property in the Medical Field. Hershey PA: IGI Global 
2017, p. 21. 
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The research undertaken for this thesis is essentially a library-based qualitative research work 
and it is basically analytical, comparative and evaluative. The research work is significantly 
theoretical and academic, employing contextual analysis of issues and an evaluative appraisal 
of the existing international legal regime. It presents the patent law as it is today and examines 
its impact on the society and the human rights law and vice versa. It uses the so-called ‘human 
rights critique’ of the current patent legislation. This is because the human rights scholars and 
activists have, from its beginnings, taken an opposing approach towards the intellectual 
property (IP) protection of essential medicines, especially the extensive patent protection 
provided under the TRIPS, due to its negative impact on the right to health. The human rights 
approach and critique of the WTO rules and IP law has been said to be the most important when 
it comes to assessing the conflict between human rights law and trade rules.5 This is so because 
the human rights framework ‘shifts the focus’ of the analysis of the impact of IPRs over the 
human right to health, by reframing the ‘existing legal discourses that privilege legal rules 
protecting intellectual property over those protecting individual rights and social values’, by 
providing ‘a mechanism to hold governments accountable for providing at least minimal levels 
of health care’, and by emphasizing ‘the need to restructure incentives for medical research and 
innovation toward the treatment of neglected diseases and the health needs of the poor’.6 
Through this method, therefore, it will be shown to the reader how these two areas of law are 
intertwined and interrelated, and how one affects the other. 
 
The thesis has chosen available documents as the sources of data for a number of reasons. First, 
the research project is largely theoretical and most of the information required is already well 
documented in different sources such as the official texts of relevant legislations, judicial 
decisions, policy papers, and annual reports of the WTO TRIPS Council as well as secondary 
sources such as the works of leading academics in the field. The research project does not 
involve the use of interviews because it investigates issues with very significant political 
implications both at national and international levels. This may create significant challenges 
when it comes to getting approvals for interviews for instance. 
 
The first chapter of this study will deal with the patents for medicines in the TRIPS Agreement. 
It will outline the protection given by the medical patents, but also the ways that the TRIPS 
Agreement provides the members with balancing this protection with other public interests. The 
                                                 
5 H. Hestermeyer. Human Rights and the WTO: The Case of Patents and Access to Medicines. Oxford: Oxford 
University Press 2007, pp. 12-15. 
6 L. R. Helfer and G. W. Austin. Human rights and intellectual property: mapping the global interface. 
Cambridge: Cambridge University Press 2011, p. 90. 
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purpose of the TRIPS Agreement will also be touched upon. Some relevant TRIPS Agreement 
Articles will be analysed in connection with human rights. Also, the Doha Declaration on 
TRIPS and Public Health will be mentioned. Further, it will discussed about the importance of 
patents. It will reason why the patent protection is necessary to get through the “valley of death” 
and to compensate for the research and development. Also, how to market the product through 
patent protection. 
 
The second chapter will look at right to health and its relevant legislation. It will open the 
definition of right to health and find out who is obliged to promote right to health. European 
Union approach to the right to health will also be discussed. In the end of the chapter, it is 
shown, how the right to health is in conflict with the relevant patent law. Thus, the comparison 
of the object and purpose of the right to health and patent law treaties will be performed. What 
is more, the enforcement of these treaties will be analysed and how this affects the practice of 
member States. 
 
The third and the final chapter will consider the means to resolve the conflict. Treaty 
interpretation and conflict resolution techniques are mentioned in this chapter. Also, superior 
norms. It is considered whether human rights, and the right to life more specifically, could be a 
peremptory norm and thus prevail over the intellectual property law. Then it will go in more 
detail into treaty interpretation as a way to find a balance between the medical patents and the 
right to life. It will look into the attitude of WTO towards the human rights in connection with 
the TRIPS Agreement and discuss the important amendment made to TRIPS Agreement. 
Additional keywords of this chapter are transition periods; the criteria of patentability; 
compulsory licences; parallel importation; limited exceptions to patent rights; and opposition 
and revocation procedures. Also some examples of the State practice are provided. In the end 
of the chapter, the new relevant provisions in regards of the TRIPS Agreement’s amendment 
will be analysed. Also, it is viewed, how the European Union incorporates this amendment in 
its legislation. 
 
The most important sources used for this study are: 
• I. Lasić. Pharmaceutical Patents, Right to Health and Access to Essential Medicines: A 
Human Rights Critique. Master’s Thesis. Lund University 2013. 
• J. A. Sellin. Does One Size Fit All? Patents, the Right to Health and Access to 
Medicines. – 62 Netherlands International Law Review 2015(3), pp. 445–473. 
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• P. Cullet. Patents and medicines: the relationship between TRIPS and the human right 
to health. – 79 International Affairs 2003(1), pp. 139-160. 
• H. Hestermeyer. Human Rights and the WTO: The Case of Patents and Access to 
Medicines. Oxford: Oxford University Press 2007. 
• L. R. Helfer, G. W. Austin. Human rights and intellectual property: mapping the global 
interface. Cambridge: Cambridge University Press 2011. 
• C. Raluca. Patents on pharmaceuticals and right to health. Master Thesis. 2016. 
Available at http://arno.uvt.nl/show.cgi?fid=142086 (Accessed 17.03.18). 
 
The author would like to express his gratitude to his family and friends for their love and 
support. 
 
Keywords: intellectual property, human rights, patents, pharmaceutical companies, State 
responsibility  
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1 Intellectual Property Covering Pharmaceuticals 
 
Intellectual property is considered as a “creation of the mind”, under which it is possible to 
patent inventions stemming from the pharmaceutical sector.7 Article 27(2) of the Universal 
Declaration of Human Rights (UDHR) draws out the Intellectual Property Rights, and it says 
that “Everyone has the right to the protection of the moral and material interests resulting from 
any scientific, literary or artistic production of which he is the author.”8 What is more, Article 
15(1)(c) of the ICESCR says that „The States Parties to the present Covenant recognize the 
right of everyone: To benefit from the protection of the moral and material interests resulting 
from any scientific, literary or artistic production of which he is the author.”9 
 
Nowadays, the most important treaty containing the intellectual property rights is the TRIPS 
Agreement, which became effective in 1995.10 It defines patent, as an exclusive private right or 
monopoly for an invention for a limited period of time (for twenty years),11 that allows for the 
patent holder to forbid other parties from using their patented invention.12 It is a requirement 
for the patent to be acquired, that the information concerning the invention is revealed to the 
public while submitting the patent.13 It should be noted that patents are only effective in the 
region that awards it. These rights allow patent holders to benefit for their efforts in creating 
the invention, by making a revenue as a result of selling the invention as a monopoly, thus 
enabling the inventor to avoid competition. Patents are believed to be a way to stimulate 
innovation and the progress of technology by allowing the patent owner to benefit from the 
prices of a monopoly stakeholder.14 
 
 
                                                 
7 World Intellectual Property Organisation (WIPO). What is Intellectual Property?. WIPO Publication No. 
450(E). Available at http://www.wipo.int/edocs/pubdocs/en/intproperty/450/wipo_pub_450.pdf (Accessed 
17.03.2018). 
8 UN General Assembly. Universal Declaration of Human Rights. 1948. Article 27 (2). 
9 UN General Assembly. International Covenant on Economic, Social and Cultural Rights. 1966. Article 
15(1)(c). 
10 WTO. Overview: the TRIPS Agreement. Available at 
https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm (Accessed 17.03.2018) 
11 Supra n 2. Article 33. 
12 Ibid. Article 28. 
13 Ibid. Article 29(1). 
14 L. R. Helfer. Pharmaceutical Patents and the Human Right to Health: The Contested Evolution of the 
Transnational Legal Order on Access to Medicines. – T.C Halliday and G. Shaffer. Transnational Legal Orders. 
Cambridge: Cambridge University Press 2015, pp. 311-339. 
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Patent rights can be upheld in courts, but on the other hand, a court can also stop the patent 
protection when effectively challenged.15 Patents are usually granted by national patent offices, 
but can be also given by regional offices, for example the European Patent Office (EPO).16  
These regional offices allow the person to file an application for patent protection in multiple 
countries, whereas countries then consider whether they allow the respective patent to be 
granted within its area.17 The World Intellectual Property Organization administered (WIPO) 
Patent Cooperation Treaty (PCT)18 has basically the same system in force.19 It is possible by 
using this system to request a patent protection in multiple signatory states to the treaty by using 
just a single application.20 
 
WIPO, being one of the agencies of the United Nations, has 191 members, and it is an 
international forum dealing with IP policy, data, services and collaboration. It strives to create 
a balanced and effective international IP system that makes innovation and creativity flourish 
for the benefit of everybody. WIPO was established in 1967 by the WIPO Convention, which 
sets out its mandate, governing bodies and procedures.21 
 
Article 27 of the TRIPS Agreement states that there is a patent protection to all fields of 
technology. This means that members cannot exclude medicines from patent protection. 
Articles 28 and 33 of the TRIPS Agreement provide patent holders a set of exclusive rights for 
a minimum period of 20 years. 
 
What is more, the TRIPS Agreement gives the members a chance to balance the patent 
protection with other public interests, such as access to medicines and public health. TRIPS 
Agreement’s objective is not limited to the protection of intellectual property rights, but instead 
it recognises the need to find a balance between the promotion of technological advantages and 
the transferral and circulation of such know-how.22 This is seen in the phrasing of Article 7 
TRIPS which was one of the key proposals made by developing countries during the 
negotiations and states as follows: 
                                                 
15 Supra n 7, p. 5. 
16 Ibid. 
17 Ibid. 
18 WIPO. Patent Cooperation Treaty (PCT), (as modified on 3 October 2001). Available at 
http://www.wipo.int/wipolex/en/treaties/text.jsp?file_id=288637 (Accessed 17.03.18). 
19 Ibid. Article 3. 
20 Ibid. 
21 WIPO. Inside WIPO. Available at http://www.wipo.int/about-wipo/en/ (Accessed 17.03.18). 
22 Supra n 2, Preamble, Articles 7-8. 
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“The protection and enforcement of intellectual property rights should contribute to the 
promotion of technological innovation and to the transfer and dissemination of technology, to 
the mutual advantage of producers and users of technological knowledge and in a manner 
conducive to social and economic welfare, and to a balance of rights and obligations.”23 
 
Article 8.1 TRIPS is conveyed more strongly and states that “members may adopt measures 
necessary to protect public health provided that such measures are consistent with the provision 
of this Agreement”.24 
 
Mentioned articles are relevant since they allow members to use measures to ensure access to 
reasonably priced medicines. However, they can be seen as limited in that they cannot be 
interpreted as general exception clauses analogous to Article XX GATT (or Article XIV 
GATS).25 However, they are important since they lay out the Agreement’s purpose and 
principles and also provide a way to interpret and implement the TRIPS Agreement. 
 
Furthermore, the Agreement lets the members decide which appropriate method of 
implementation to use in their national legal system with the requirement that minimum 
standards of the TRIPS Agreement are met.26 Terms, such as ‘inventiveness’ and ‘novelty’27, 
leave room for interpretative flexibility to take into account what is most favourable to social 
welfare and public health. 
 
Additionally, the Agreement also provides a selection of options for developing countries to 
strike balance between patent protection and the right of access to medicines.28 Consequently, 
a number of tools are available under the Agreement to developing members to make sure that 
the balance is in existence, for example, compulsory licenses, parallel importation and ‘Bolar’ 
exemption. 
 
 
 
                                                 
23 Ibid. Article 7. 
24 Ibid. Article 8.1. 
25 H. Hestermeyer. Human rights and the WTO: the case of patents and access to medicines. Oxford University 
Press: Oxford 2007, p. 58. 
26 Supra n 2, Article 1. 
27 Ibid. Article 27. 
28 Ibid. Articles 30 and 31. 
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1.1 Importance of Patent Protection 
 
By using the intellectual property protection in a correct way, it is possible for the relevant 
parties to reduce their risks in a significant manner, as the market success of a novel product is 
affected by many different factors. It allows for the patent holders, who have contributed to the 
invention of the process, to gain acceptable benefits. 
 
Innovative technology can be brought to the market by a proper IP protection granting it an 
important role. IP also can be used by the technology-based enterprises to enhance 
competitiveness, while it does not matter if the companies are offering new or simply enhance 
merchandise or delivering services that are based on a new or simply upgraded technological 
know-how. 
 
By creating a successful invention, technology-based companies enjoy more productive ways 
of running their business or even can put to market a completely now product. When the  
The enhanced effectiveness of the business is the outcome of additional value that reinforces a 
greater flow of income or advanced efficiency. 
 
It is imperative to handle a ground-breaking idea as a secret if it is the wish of the enterprise to 
gain some profits in commercialising the idea. It does not matter whether the business innovates 
in order to grow (general strategy of business) or it is just a counter-measure to the current 
market situation and its developments. If the secret comes out, then the others can use it to their 
own benefit and the monopoly advantage of holding this idea would be lost. 
 
It has been proved by the empirical evidence that trade secrets are usually being used more by 
small and average-sized businesses, who tend to shy away from using patents in order to protect 
the work they have created so they could stay in competition.29 These kinds of businesses 
explain this kind of behaviour with the reason that the patent system is a complex one with 
relatively high expenses. Australian-based study reveals that only 44 percent of the companies 
chose patent protection while an enormous 74 percent preferred to use trade secrets for keeping 
their ideas in secret. The size of the company was shown to play a big role in determining which 
                                                 
29 M. Rogers. The Definition and Measurement of Innovation. Melbourne Institute Working Paper No. 10/98. 
1998, p. 14. Available at https://pdfs.semanticscholar.org/c71a/9e4a99732746d58da82f235799000901ff8e.pdf 
(Accessed 17.03.18). 
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way to go, for example 75 percent of companies with 500 or more employees chose patent 
protection and only 35 percent of companies with 20 or less employees relied on patents.30 
 
Some (mostly, small and averaged sized companies, as explained above) see that innovation is 
being impeded by the complexity of the patent system and also it relatively high costs while for 
example, writing a patent claim or dealing with the “prior art” search, then the patents can be 
something that brings in more revenue, if used in a tactical manner, even for these small and 
average-sized businesses.31  
 
For a thought that may result in a patentable innovation, the inevitable decision between the 
utilization of either the trade secret route or the patent route to defend it ought to be viewed as 
a key business decision that ought to be taken just at a propelled phase of its improvement when 
every one of the prerequisites of patentability are met, specifically, statutory subject matter, 
novelty, inventive step/non-obviousness, capable of industrial application, and suitable 
disclosure. While reaching that point, the decision would rely upon the idea of the creation, its 
business forthcoming, the nature of rivalry, the likelihood of its autonomous creation by rivals 
and the capacity of contenders to figure out it easily from the item created by utilizing it.32 It 
ought, nevertheless, be brought up that whatever the ultimate conclusion, originally it must be 
safe-guarded as a trade secret so that, later on a piece of it may be patented and whatever 
remains of it may in any case remain to be an associated trade secret and know-how, or implicit 
information that is possessed by entities related with the patent. 
 
The facts contained in present patent files (patent facts) performs an important role inside the 
thought, screening and development of an idea. Such information can provide useful perception 
into whether or not an idea is new or no longer and whether to proceed similarly in growing an 
idea. Furthermore, proper evaluation of patent facts may additionally provide a perception into 
the method of capable competition and about developments in technology.33 
 
 
 
                                                 
30 Ibid. 
31 C. M. Kalanje. Role of Intellectual Property in Innovation and New Product Development. Available at 
www.wipo.int/sme/en/documents/ip_innovation_development_fulltext.html#P64_14377 (Accessed 17.03.18). 
32 Ibid. 
33 Ibid. 
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1.1.1 Stage of Research and Development 
 
The efforts of a company, that it assumes in doing research to discover an original idea and then 
making it happen, can be measured in numerous indicators. Some of these are, total sales, data 
on innovation, expenses on product research and its development, innovation policies and the 
size of the company.34 Intellectual property often influences the mentioned indicators in a direct 
or indirect manner. Thus, the tools of intellectual property continue their importance from the 
stage of creating an original idea to the stage at hand. So, if the company has not decided if they 
would like to go for the patent protection, then the trade secret is still a crucial measure of 
protection. Because no one would want that the contenders get their hands on sensitive data, 
then trade secrets are pertinent in also research and development phase. Rivals could seriously 
damage the competitive advantage, if information leaks about the final product.35 
 
It is at this stage, that the scientists of a product should take advantage of data sources which 
can make their venture flourish. Significant source of data in the face of patent documentation 
is often totally  
During this period, researchers should at times consult several sources of data that would offer 
input for the success of their venture. Patent documents continue to be a significant source of 
data that is often not used enough.36 This documentation has some valuable data that could be 
used by the company to keep away from needless use of their capital, be it time or cash, while 
in the process of research and development, which could lead to the decrease of normally great 
research and development expenses. Documents about patents can also be used to gain data, 
which offer the possibility to enhance the merchandise or to assemble the invention in an easier 
wat, which can shorten the usually long time of commercialising the goods.37 
 
1.1.2 Most Crucial Phase of Innovation 
 
To popularise the original concepts of technology in the marketplace, they need, quite often to 
be developed in a further technical manner. Small and average-sized companies often are not 
able to do these kinds of developments, for example, prototype testing and advantaging, since 
they do not own such facilities or assets. While these small companies might turn to the research 
                                                 
34 R.G.M. Kemp and others. Innovation and firm performance differences between small and medium-sized 
firms. 2003, p.7. Available at http://ondernemerschap.panteia.nl/pdf-ez/n200213.pdf (Accessed 17.03.18). 
35 Supra n 55. 
36 Ibid. 
37 Ibid. 
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institutes, innovation centres, technology parks, other companies, universities, or to say shortly 
external facilities, then the intellectual property protection keeps the ideas safe and sound. What 
is more, when bringing a product to the market by a partnership and developing the invention 
in the future, then a strong negotiating position is offered by the ownership of intellectual 
property protection while trying to establish such a partnership. It is in the interest of both 
parties to initially clarify the issues of intellectual property ownership to evade potential 
conflicts that may rise.38 
 
Even the greatest goods need, in order to be properly commercialised, some fine marketing 
experience and the inventors of these products lack these kinds of skills.39 The most crucial 
stage is commercialising the goods and it is difficult for these creators of inventions, especially 
the small and average-sized companies. A lot of potentially good inventions are lost in this 
stage because they do not get outside help or are just not fit for the market.40 
 
Patents can be relied on to attract investors to the idea, these could be financial organisations, 
venture capitalists, seed capital and other business angels who can offer some support to 
commercialise the product. Xerography is a good example to be considered. Xerograph was 
invented by Mr Carlson in 1937, but gained its patent protection in 1939. Mr Carlson struggled 
for almost eight long years to find a willing business angel to support his creation. The invention 
was finally made effectively suitable for market place by the firm named Haloid, which 
happened in year 1950.41 It can be reasoned that the choice by the Haloid Company to support 
the creation, was considerably affected by the fact that Mr Carlson had patent on his creation. 
Ideas that are potentially quite good and innovative are ended in this stage. By getting a patent 
protection on an idea, an inventor can safeguard the creation so it would not lose its value. It is 
an often occurrence that to keep the idea alive, it needs some support from third parties, whether 
this help is connected to marketing, finance, or technical awareness. Possessing intellectual 
property protection can be a great factor in determining the choices of these third parties 
whether they assist in commercialising the product or not.42 
 
                                                 
38 Ibid. 
39 P. A. Fisher. Common Stocks and Uncommon Profits and Other Writings. Wiley: Wiley Investment Classics 
2003, p. 124. 
40 Supra n 55. 
41 Xerox. The Story of Xerography. Available at 
https://www.xerox.com/downloads/usa/en/s/Storyofxerography.pdf (Accessed 17.03.18). 
42 Supra n 55. 
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It may be easier for the players holding intellectual property rights to find business partners 
with fair terms and conditions. The partners can offer research and development facilities or 
even ways to commercialise the product.43 If one holds a patent protection, then the business 
angels are more prone to invest in the product and this helps to commercialise the merchandise. 
These investors play a major role in.44 
 
1.2 European Union Practice and Approach 
 
The European Patent Convention (EPC), also known as the Convention on the Grant of 
European Patents of 5 October 1973, is a multilateral treaty instituting the European Patent 
Organisation and providing an autonomous legal system according to which European patents 
are granted.45  
 
Under the Article 52 (1) of the EPC it states that “European patents shall be granted for any 
invention in all fields of technology, provided that they are new, involve an inventive step and 
are susceptible of industrial application”.46  
 
Article 53 then goes on to deal with the exceptions of patentability and states that European 
patents shall not be awarded for:  
“(a) inventions the commercial exploitation of which would be contrary to "ordre public" or 
morality; such exploitation shall not be deemed to be so contrary merely because it is prohibited 
by law or regulation in some or all of the Contracting States;   
(b) plant or animal varieties or essentially biological processes for the production of plants or 
animals; this provision shall not apply to microbiological processes or the products thereof;  
(c) methods for treatment of the human or animal body by surgery or therapy and diagnostic 
methods practised on the human or animal body; this provision shall not apply to products, in 
particular substances or compositions, for use in any of these methods.”47 
 
Article 54 (1) addresses the notion of novelty and states that: “An invention shall be considered 
to be new if it does not form part of the state of the art.”48 Article 54 (2) adds that: “The state 
                                                 
43 Ibid. 
44 Ibid. 
45 European Patent Office. Guide for applicants: How to get a European patent. Available at 
https://www.epo.org/applying/european/Guide-for-applicants/html/e/ga_a_ii.html (Accessed 17.03.18). 
46 WIPO. Convention on the Grant of European Patents (European Patent Convention). 1973. Article 52 (1). 
47 Ibid. Article 53(a)-(c). 
48 Ibid. Article 54(1). 
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of the art shall be held to comprise everything made available to the public by means of a written 
or oral description, by use, or in any other way, before the date of filing of the European patent 
application.”49 
 
According to the Article 56: “An invention shall be considered as involving an inventive step 
if, having regard to the state of the art, it is not obvious to a person skilled in the art.”50 This 
assessment is conducted according to the "could-would approach" and the following method of 
consideration is applied: 
 
It is considered whether there is any teaching in the prior art as a whole that would (not simply 
could, but would) have prompted the skilled person, faced with the objective technical problem, 
to modify or adapt the closest prior art while taking account of that teaching, thereby arriving 
at something falling within the terms of the claims, and thus achieving what the invention 
achieves.51 Put differently, the main factor is that the person with relevant experience would do 
it because there was something in the earlier art that made him do it for the purpose of improving 
or solving some technical issue, and not because this person just modified or adapted the closest 
earlier art. 
 
Lastly, Article 57 dealing with the patentability in the EPC states that: “An invention shall be 
considered as susceptible of industrial application if it can be made or used in any kind of 
industry, including agriculture.”52 "Industry" should be understood in its broad sense as 
including any physical activity of "technical character", i.e. an activity which belongs to the 
useful or practical arts as distinct from the aesthetic arts; it does not necessarily imply the use 
of a machine or the manufacture of an article. Thus, Art. 57 excludes from patentability very 
few "inventions" which are not already excluded by the list in Art. 52(2).53 
 
Article 83 is about the revelation of information, and quite an important Article. By this Article, 
it is required that the applicant for the patent reveals the information about the product that he 
                                                 
49 Ibid. Article 54(2). 
50 Ibid. Article 56. 
51 European Patent Office. Guidelines for Examination. Available at http://www.epo.org/law-practice/legal-
texts/html/guidelines/e/g_vii_5_3.htm (Accessed 17.03.2018). 
52 Supra n 30, Article 57. 
53 European Patent Office. Guidelines for Examination. Available at https://www.epo.org/law-practice/legal-
texts/html/guidelines/e/g_iii_1.htm (Accessed 17.03.2018). 
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is or she is seeking intellectual property protection for, so that it could be replicated by an 
experienced individual.54 
 
In 1977, the international body called the European Patent Organisation (EPO) started its work, 
which derived from the European Patent Convention. It consists of two authorities: the 
Administrative Council and the European Patent Office. The latter one is the executive body of 
the EPO and it provides the inventors with a single application process, enabling these inventors 
to receive protection of the patent in more than 40 countries. The Administrative Council 
supervises the EPO. Organisation’s member states’ representatives compose the Administrative 
Council. Currently, EPO consists of 38 member states. However, there are additional 4 non-
member states that the European Patent is recognised in, which of two of these are European 
states and two non-European. Board of appeal of the EPO deals with the appeals against the 
decisions of the EPO. It is a part of the organisation’s structure, but the appeal board is 
considered to be independent from the Office when making their decisions. Board of appeal is 
bound only by the European Patent Convention.55 
 
1.2.1 European Union Biotech Directive 
 
The European Biotechnology Directive creates the presumption that biological inventions are 
patentable subject matter. Recital 18 of the European Biotechnology Directive implies that the 
1998 patent laws of member countries inadequately dealt with biotechnological inventions. It 
states that, because the patent system provides insufficient incentive for encouraging research 
into and production of biotechnological medicines which are needed to combat rare or “orphan” 
diseases, the Community and the Member States have a duty to respond adequately to this 
problem.56 
 
Article 3 of the Directive states that:  
“1. For the purposes of this Directive, inventions which are new, which involve an inventive 
step and which are susceptible of industrial application shall be patentable even if they concern 
a product consisting of or containing biological material or a process by means of which 
biological material is produced, processed or used. 
                                                 
54 Supra n 30, Article 83. 
55 European Patent Office. Governance. Available at https://www.epo.org/about-us/governance.html (Accessed 
17.03.2018). 
56 Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of 
biotechnological inventions. Recital 18. 
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2.   Biological material which is isolated from its natural environment or produced by means of 
a technical process may be the subject of an invention even if it previously occurred in nature.”57 
Thus, it is similar to the requirements brought out in the EPC and TRIPS Agreement, since 
novelty, inventive step and industrial application is referred to. 
 
Finally, Article 4 of the Directive lists matters that are considered to be unpatentable. Article 6 
underlines the inventions that cannot be patented because their commercial abuse would be 
conflicting to public order or morality, for example altering the germ line genetic identity of 
humans and the procedure of altering the genetic identity of animals if there is no significant 
benefit to humans or animals.58 
 
1.2.2 TRIPS Application within the EU 
 
The Court of Justice of the European Union (CJEU) decided in its judgment of 18 July 201359, 
that following the enforcement of the Lisbon Treaty on 1 December 2009, TRIPS Agreement’s 
provisions wholly belong to the field of the common commercial policy, which means that the 
national courts of Member States do not have the jurisdiction to apply and/or interpret the 
TRIPS Agreement provisions on their own anymore. This was truly a controversial shift from 
the judgments of 14 December 200060 and 11 September 200761, in which CJEU found that in 
the fields (e.g. patents) where the harmonisation of the Community has not yet been made, the 
Member States remained primarily competent.62 
 
In its Opinion 1/1994,63 the CJEU clarified that the EC and its Member States were jointly 
competent to conclude the Final Act Embodying the Results of the Uruguay Round of 
                                                 
57 Ibid. Article 3.  
58 Ibid. Article 6. 
59 Judgment of the Court (Grand Chamber), 18 July 2013. Daiichi Sankyo Co. Ltd and Sanofi-Aventis 
Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon. 
60 Judgment of the Court of 14 December 2000. Parfums Christian Dior SA v TUK Consultancy BV and Assco 
Gerüste GmbH and Rob van Dijk v Wilhelm Layher GmbH & Co. KG and Layher BV.  
61 Case C-431/05. Merck v. Merck Generics. JUDGMENT OF THE COURT (Grand Chamber), 11 September 
2007. Judgment of the Court (Grand Chamber) of 11 September 2007. Merck Genéricos - Produtos 
Farmacêuticos Ldª v Merck & Co. Inc. and Merck Sharp & Dohme Ldª. 
62 M. M. Mora. The Practical Consequences of the CJEU Judgment of 18 July 2013 Changing Its Doctrine on the 
Respective Competences of the EU and its Member States to Apply the TRIPS Agreement: Have We Seen the 
Tip of the Daiichi Iceberg Yet?. – IIC – 48 International Review of Intellectual Property and Competition Law 
(7) 2017, pp. 784–812, p 784. 
63 Opinion of the Court of 15 November 1994. Competence of the Community to conclude international 
agreements concerning services and the protection of intellectual property - Article 228 (6) of the EC Treaty. 
Opinion 1/94. 
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Multilateral Trade Negotiations,64 which includes the TRIPS Agreement. The prudent approach 
followed by the CJEU in this case was also plotted by the CJEU in its judgments of 14 
December 2000 (Christian Dior and AsscoLayher) and 11 September 2007 (Merck Genericos 
et al.). In these cases, it found that in a field where the EC has not yet legislated and which falls 
within the competence of the Member States, the protection of intellectual property rights – and 
measures adopted for that purpose by the judicial authorities – do not fall within the scope of 
EC waters. Accordingly, the CJEU added that EC law neither requires nor forbids courts of 
Member States to apply and interpret provisions of the TRIPS Agreement governing matters 
such as patents, for which Member States continue to have the primary competence. 
 
This state of affairs changed dramatically six years later. In its judgment of 18 July 2013, the 
CJEU, leaving aside the calm waters laid down by Opinion 1/1994 and its saga, the answer 
primarily proposed by the Advocate General, and the opinions of all the parties who filed 
observations, came to the conclusion that after the entry into force of the Lisbon Treaty on 1 
December 2009, the provisions of the TRIPS Agreement fall within the scope of the EU’s 
common commercial policy. This judgment was handed down in response to a referral for a 
preliminary ruling sent by a Greek court regarding the obligations of protection introduced by 
the TRIPS Agreement in relation to patents already granted when TRIPS came into force. 
 
As a result of the judgment of 18 July 2013 the European Union is trying to introduce a 
“European patent with unitary effect65” and a “Unified Patent Court” established by an 
international treaty alien to the EU.66 This patent will be a classical European patent granted by 
the European Patent Office that will have “unitary effect” throughout the EU, if the applicant 
chooses so within one month after the granting of the patent. Although, during the early stages 
of the drafting of the Regulation seeking to introduce this patent, the plan was that it would be 
governed by EU law – in the end this idea was abandoned. The reason is that some stakeholders 
considered that the CJEU, due to its lack of specialization, is not well equipped to decide cases 
on patent matters. They thought that by removing substantive patent law from the text of the 
Regulation, the risk of having cases referred to the CJEU would be kept to a minimum. This 
explains why, at the last minute, Arts. 6–8 (substantive patent law) were removed from the text 
of the Regulation. Instead, substantive patent law was taken to Arts. 25–30 of the “Agreement 
                                                 
64 WTO. Final Act Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations. Available 
at https://www.wto.org/english/docs_e/legal_e/03-fa_e.htm (Accessed 17.03.18). 
65 Regulation (EU) 1257/2012 of the European Parliament and of the Council of 17 December 2012 
implementing enhanced cooperation in the area of the creation of unitary patent protection. O.J. 2012, L 361/1. 
66 Agreement on a Unified Patent Court. O.J. 2013, C 175/1. 
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on a Unified Patent Court”,67 an international treaty that will introduce a new Patent Court 
competent to resolve disputes relating to the European patent with unitary effect and classical 
European patents.68 
 
 
 
  
                                                 
67 Ibid. 
68 Supra n 46, pp. 797-798. 
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2 Human Right to Health 
 
The right to health is an important part of our human rights and of our understanding of a life 
in dignity. Worldwide, it was first expressed in the Constitution of the World Health 
Organization (WHO), which defines health as “a state of complete physical, mental and social 
well-being and not merely the absence of disease or infirmity”. What is more, it states that “the 
enjoyment of the highest attainable standard of health is one of the fundamental rights of every 
human being without distinction of race, religion, political belief, economic or social 
condition.”69 UDHR70 also stated health as part of the right to an adequate standard of living.71 
Another distinction of right to health was made in International Covenant on Economic, Social 
and Cultural Rights72. 
 
All States have signed at least one treat that promotes the right to health, thus this right is 
important globally. States strive to uphold this right by declaring it internationally, enforcing it 
in its legislature and policies, and also mentioning it at international forums. Human rights 
treaty monitoring bodies, WHO and Commission on Human Rights have recently turned their 
attention to the right to the highest attainable standard of health. In 2002 it was created by 
Commission on Human Rights the mandate of Special Rapporteur on the right of everyone to 
the highest attainable standard of physical and mental health. 
 
2.1 The Basis: Universal Declaration of Human Rights 
 
As the name suggests, Universal Declaration of Human Rights (UDHR) is not a treaty, but a 
declaration. Its purpose of adoption was to define the concepts of the terms “human rights” and 
“fundamental freedoms” that appear in the UN Charter – a document that is binding on all its 
signatory states. For this reason, the Universal Declaration of Human Rights is a fundamental 
constitutive document of the United Nations. In addition, many international lawyers believe 
that the Declaration forms part of customary international law and is a powerful tool in applying 
diplomatic and moral pressure to governments that violate any of its articles. The Declaration 
has served as the foundation for two binding UN human rights covenants: the International 
Covenant on Civil and Political Rights and the International Covenant on Economic, Social and 
                                                 
69 Preamble to the Constitution of the World Health Organization as adopted by the International Health 
Conference, New York, 19-22 June, 1946; signed on 22 July 1946 by the representatives of 61 States (Official 
Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948. 
70 Supra n 8. 
71 Ibid. Article 25. 
72 Supra n 9. 
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Cultural Rights. It serves as “the foundation for the international code of human rights”73 and 
the concept of “humanitarian duty” of aid by countries more developed to help less developed 
countries is envisioned in it.74 According to the Article 25(1) of the UDHR, everyone has the 
right to medical care.75 
 
2.1.1 Lawfully Binding Covenant 
 
The International Covenant on Economic, Social and Cultural Rights (ICESCR) is a treaty, 
which multiple signatories, adopted by the United Nations General Assembly on 16 December 
1966, and in force from 3 January 1976, which in its Article 12 ICESCR recognises and defines 
the right to health.76 As ICESCR is a treaty then it is lawfully binding to its parties. Hence, the 
ICESCR delivers the foundation for the legal obligations under the right to health77 that States 
parties need to conform with. 
 
Article 12 of the Covenant recognises the right of everyone to “the enjoyment of the highest 
attainable standard of physical and mental health”.78 "Health" is understood not just as a right 
to be healthy, but as a right to control one's own health and body, and be free from interference 
such as torture or medical experimentation.79 Article 12.2 requires parties to take specific steps 
to improve the health of their citizens, including reducing infant mortality and improving child 
health, improving environmental and workplace health, preventing, controlling and treating 
epidemic diseases, and creating conditions to ensure equal and timely access to medical services 
for all. These are considered to be "illustrative, non-exhaustive examples", rather than a 
complete statement of parties' obligations.80 
 
Committee on Economic, Social and Cultural Rights, which is a body of human rights experts, 
deals with the monitoring of implementation of the ICESCR. It consists of 18 independent 
                                                 
73 G. Backman and others. Health systems and the right to health: an assessment of 194 countries. – 372 The 
Lancet 2008, p. 2047. Available at 
http://www.who.int/medicines/areas/human_rights/Health_System_HR_194_countries.pdf (Accessed 17.03.18). 
74 M. Gumbel. Is Article 31 Bis Enough? The need to Promote Economies of scale in the International 
Compulsory Licensing System. 22 Temple Int’t and Comp. L. J. 2008, p 164. Available at 
http://www.temple.edu/law/ticlj/ticlj22-1Gumbel.pdf (Accessed 17.03.18). 
75 Supra n 8, Article 25(1). 
76 United Nations Committee on Economic, Social and Cultural Rights. CESCR General Comment No. 14: The 
Right to the Highest Attainable Standard of Health (Art. 12). 11 August 2000. Available at 
http://www.ohchr.org/Documents/Issues/Women/WRGS/Health/GC14.pdf (Accessed 17.03.18). 
77 H. V. Hogerzeil and others. Is access to essential medicines as part of the fulfilment of the right to health 
enforceable through the courts?. – 368 The Lancet 2006, p. 305. 
78 Supra n 9, Article 12.1. 
79 Supra n 76, paragraph 9. 
80 Supra n 9 Article 12.2. 
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human rights experts, elected for four-year terms, with half the members elected every two 
years.81 All states parties are required to submit regular reports to the Committee outlining the 
legislative, judicial, policy and other measures they have taken to implement the rights affirmed 
in the Covenant. The first report is due within two years of ratifying the Covenant; thereafter 
reports are due every five years. The Committee then on the basis of the reports provided to 
them delivers its concluding observations to the states, which contains Committee’s concerns 
and recommendations.82  
 
The United Nations Committee on Economic, Social and Cultural Rights delivered a document 
known as the General Comment 14, which contains a legally binding explanation about the 
right to health.83 It is declared by this Comment84 that the right to medicinal services comprises 
matters of access to essential medicines as defined by the World Health Organisation’s Action 
Programme on Essential Drugs85. What is more, the Comment says that the States have the duty 
to safeguard the right to health and also the Comment requires to abstain from interfering with 
this right, whether it is direct or indirect in its nature. It is also the task of the States to implement 
suitable administrative measures and legislation, and inhibit third parties from interfering with 
the assurances provided by the right.86 
 
It should be noted that ICESCR Member States have a pressing duty to follow the Article 12 to 
assure that the right to health is attained without any discrimination, however, it also takes into 
account the limits of available resources of its Member States and provides for a steady 
realisation of the right to health.87 
 
 
 
 
 
 
                                                 
81 United Nations Human Rights Office of the High Commissioner. COMMITTEE ON ECONOMIC, SOCIAL 
AND CULTURAL RIGHTS. Available at http://www.ohchr.org/en/hrbodies/cescr/pages/cescrindex.aspx 
(Accessed 17.03.2018). 
82 United Nations Human Rights Office of the High Commissioner. COMMITTEE ON ECONOMIC, SOCIAL 
AND CULTURAL RIGHTS. Available at 
http://www.ohchr.org/EN/HRBodies/CESCR/Pages/WorkingMethods.aspx (Accessed 17.03.2018). 
83 Supra n 76. 
84 Ibid. 
85 Supra n 77, p. 305. 
86 Supra n 1, p 148; supra n 76. 
87 Supra n 77, p. 306. 
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2.1.2 Essence of Right to Health 
 
Everyone has the right to health. It relates to both the right of individuals to obtain a certain 
standard of health and health care, and the State obligation to ensure a certain standard of public 
health with the community generally. 
 
The World Health Organization defines the right to health as a complete state of physical, 
mental and social well-being, and not merely the absence of disease or infirmity. States should 
ensure both freedoms and entitlements. The former include the right to control one’s health and 
body, including sexual and reproductive freedom, and the freedom from interference such as 
torture, non-consensual medical treatment and experimentation. Entitlements include access to 
adequate health care facilities and services, as well as appropriate State measures in relation to 
the socio-economic determinants of health, such as food, water and sanitation, safe and health 
working conditions, housing, and poverty.88  
 
According to CESCR, the right to health also extends to underlying determinants of health in 
addition to timely and appropriate health care, thus making it a comprehensive right that 
comprises a wide range of elements that would lead to having a health life.89 Right to health 
entails rights and freedoms, such as the freedom to control our own health, but also rights such 
as: the right to a scheme of health protection that provides for the equality of prospects in order 
for individuals to enjoy the highest attainable level of health; the right to prevention, treatment 
and control of diseases and access to vital medications.90 Thus, the right to health is not to be 
understood as a right to be healthy.91 
 
Therefore, medicines must be available, accessible, acceptable and of decent quality.92 
Available means that functioning public health and health-care facilities, goods and services, 
as well as programmes, have to be available in sufficient quantity within the State party, 
however, this is connected to the capacity of a State to offer these facilities. Essential should, 
however, be provided, as in safe and potable drinking water and adequate sanitation facilities, 
hospitals, clinics and other health-related buildings, trained medical and professional personnel 
                                                 
88 World Health Organisation. Human rights and health. Available at 
http://www.who.int/mediacentre/factsheets/fs323/en/ (Accessed 17.03.2018). 
89 Supra n 76, para 11. 
90 Ibid. 
91 Ibid., paras 7-8. 
92 Ibid., para 12. 
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receiving domestically competitive salaries, and essential drugs.93 Accessible means that health 
facilities, goods and services have to be available to everybody indiscriminately, within the 
authority of the State party. Accessibility has four overlying dimensions:  
1. Non-discrimination: health facilities, goods and services must be accessible to all, 
particularly the most defenceless or disregarded units of the populace, legally and 
factually, without discrimination on any of the forbidden grounds; 
2. Physical accessibility: health facilities, goods and services must be within harmless 
physical scope for all units of the populace, particularly defenceless or disregarded 
groups, for example cultural minorities and aboriginal inhabitants, females, youngsters, 
teenagers, elderly, people with disabilities and people with HIV/AIDS. Accessibility 
similarly suggests that medical services and fundamental elements of health, for 
example non-toxic and drinkable water and suitable hygiene establishments, are within 
harmless physical grasp, as well as in rural regions. Accessibility further comprises 
suitable access to constructions for people with disabilities; 
3. Economic accessibility (affordability): health facilities, goods and services must be 
inexpensive for everybody. Fee for health-care services, as well as services connected 
to the fundamental elements of health, has to be founded on the principle of fairness, 
guaranteeing that these services, whether privately or publicly offered, are of reasonable 
price for everybody, taking into account socially underprivileged people. Equity stresses 
that poorer households should not be excessively weighed down with health costs as 
related to wealthier households; 
4. Information accessibility: accessibility comprises the right to seek, receive and impart 
information and concepts regarding health problems. Nevertheless, accessibility of 
information should not harm the right to have private health data treated with 
discretion.94 
Acceptability means that all health facilities, goods and services must be respectful of medical 
morals and ethnically suitable, for example respectful of the culture of individuals, minorities, 
persons and societies, thoughtful to sex and life-cycle requirements, as well as being intended 
to respect privacy and increase the health status of those concerned.95 Quality indicates that as 
well as being ethnically adequate, health facilities, goods and services must also be 
scientifically and medically fitting and of decent quality. This necessitates, inter alia, capable 
                                                 
93 Ibid., para 12(a). 
94 Ibid., para 12(b). 
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medical staff, scientifically accepted and unexpired drugs and hospital gear, non-toxic and 
drinkable water, and acceptable hygiene.96  
 
2.2 State Obligation to Uphold Public Health 
 
Since the right to health is included in a number of international human rights treaties, then it 
is first and foremost the states’ obligation to enforce the right to health and human rights 
standards in their respective territory.97 ICESCR demands states to realise the right to health, 
but it also takes into account the assets of the relevant country.98 It is obvious that different 
states have different capacities to fulfil the obligations arising from the ICESCR. This, however, 
does not mean that the states can sit still and do nothing, they must take reasonable steps in 
their respective capacity to strive in the direction of the full realisation of the right to health.99  
 
States have three different responsibilities, firstly, the responsibility to respect, which means 
that the state should refrain from taking steps that could have opposing effects on people’s 
health (negative responsibility); secondly protect which means that the states have to set in 
motion laws or other measures that would ensure equal access to health care and also health-
related services, which are usually provided by third parties; and lastly, fulfil, which means 
basically that the state must actually make sure that the full realisation of the right to health is 
implemented (latter ones being positive responsibilities).100 Though fulfilling the right to health 
can be through progressive realisation, it is, however, required that each state takes considered 
steps toward the full realisation of the right and that they provide short-term solutions to respect 
the right to health.101 
 
Medicine and public health, which are connected, but at the same time quite dissimilar terms, 
form the modern notion of health.102 Public health is concentrated on the health of the 
population as a whole, while medicine is usually focused on the health of a person.103 It is 
unavoidable that when the concept of health is transported into the human rights field as the 
                                                 
96 Ibid., para 12(d). 
97 H. Hannum. The Status of the Universal Declaration of Human Rights in National and International Law. – 25 
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98 Supra n 9, Article 2.1. 
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100 Ibid. paras 33-36. 
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States Parties’ Obligations (Art. 2, Para. 1, of the Covenant). Para 10. 
102 J. M. Mann and others. Health and Human Rights: A Reader. New York and London: Routledge 1999, pp 7-
8. 
103 Ibid. 
27 
 
right to health, that the public health is merged into the right to health. Clarification between 
the notions is further contemplated by the fact that public health aims for the protection of 
population, while human rights are suggestively based on the guarantee of individual 
protection.104  
 
It is possible in the international human rights law that the public health restrains the other 
human rights. Therefore, it is possible that in case there is a widespread illness, the public health 
may derogate from individual liberties to protect civilisation. It has in fact become a trend in 
international health law, thus making obligatory health measures quite familiar in contemporary 
society.105 It is justified on the grounds of public health and hence in sync with overall human 
rights values. In the case of epidemics, individual privileges of liberty of movement, identity, 
discretion, dignity, religion, expression and association may be limited.106 
 
The notion of public health is used a basis for the limitation of some human rights (particularly 
in the health context), however, it is not directly incited into the ICESCR and UDHR.107 It can 
be justified on the basis that public health is in fact an obligatory measure in health law, and 
also because public health is closely connected to public order.108  
 
It is permitted for the state to take actions in case of grave risks to the whole population or to 
people in the population, according to the principle 25 from Siracusa Principles.109 Furthermore, 
international rules propagated by the WHO validate restrictive measures on the basis of public 
health.110 The most relevant is still the Article 12 of ICESCR, which is used by the state for the 
inhibition of an epidemic illness. 
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2.3 European Union Approach 
 
The Charter of Fundamental Rights of the European Union111 (the Charter) brings together the 
fundamental rights of everyone living in the European Union (EU). It was introduced to bring 
consistency and clarity to the rights established at different times and in different ways in 
individual EU Member States. The Charter sets out the full range of civil, political, economic 
and social rights based. The Charter became legally binding on EU Member States when the 
Treaty of Lisbon entered into force in December 2009. 
 
The Charter is sometimes confused with the European Convention on Human Rights. Although 
containing overlapping human rights provisions, the two operate within separate legal 
frameworks. The Charter of Fundamental Rights of the European Union was drafted by the EU 
and is interpreted by the Court of Justice of the European Union. The European Convention on 
Human Rights, on the other hand, was drafted by the Council of Europe in Strasbourg and is 
interpreted by the European Court of Human Rights. The Charter can be seen as the overarching 
framework for human rights in the EU, of which the European Convention on Human Rights 
forms only one part, albeit an important one. 
 
According to Article 6 of the Treaty on EU112 the Union recognises the rights, freedoms and 
principles set out in the Charter of Fundamental Rights of the European Union. The provisions 
of the Charter shall not extend in any way the competences of the Union as defined in the 
Treaties. The Union complies with the European Convention for the Protection of Human 
Rights and Fundamental Freedoms. Such accession shall not affect the Union's competences as 
defined in the Treaties. Fundamental rights, as guaranteed by the European Convention for the 
Protection of Human Rights and Fundamental Freedoms and as they result from the 
constitutional traditions common to the Member States, shall constitute general principles of 
the Union's law.113 
 
According to the Charter of Fundamental Rights of the EU “everyone has the right of access to 
preventive health care and the right to benefit from medical treatment under the conditions 
established by national laws and practices. A high level of human health protection shall be 
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ensured in the definition and implementation of all Union policies and activities”114. Thus, 
Article 6 of the Treaty on the European Union and its access to vital medication and the right 
to health are equivalent in importance with the founding treaties of the EU.115 
 
2.4 Conflict with Patent Law 
 
Having established the concept and importance of the patents and the right to health, it is now 
time to consider how these two rights and their enforcement differ with each other.  
 
The object and purpose of the ICESCR and the TRIPS Agreement are different.116 ICESCR is 
focused on human rights and promotes as a crucial element the right to health, while TRIPS is 
mainly focused on intellectual property rights. They have different starting points and main 
characteristics.117 The High Commissioner for Human Rights has said that there remain 
“fundamental differences of approach” between the two.118 The Special Rapporteur on the right 
to health has further said that TRIPS bears upon crucial elements of the right to health.119 
 
International human rights law and TRIPS are also enforced in different ways. TRIPS is under 
the WTO dispute settlement mechanism and if a WTO member is found to be in violation of its 
obligations the Dispute Settlement Body may, as a last option, allow the complainant to 
withdraw trade or impose other sanctions against the violator.120 The mere possibility of cross-
retaliation is a powerful incentive, particularly for developing members, to comply with their 
TRIPS obligations.  
 
The ICESCR, however, does not have an enforcement mechanism as effective as the WTO does 
and, even though human rights are supposed to be morally superior, the lack of enforcement 
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makes their position weaker compared to WTO procedures. Thus, it is understandable why 
members tend to comply more with the obligations of the TRIPS rather than the ICESCR. 
 
Mostly in developing and least developed countries, it has been noted that high fees stemming 
from the strong patents on medicines, can, in a lot of cases, impair the access to essential 
drugs.121 There are two different schools of thought which concern the relationship between the 
intellectual property rights and the right to health. 
 
On one side, it has been argued that the two rights are in fact in conflict, this because the 
protection granted by the IP rights undermines the right to health. As a solution to conflict, it 
has been suggested that when the responsibilities from different treaties conflict, then the human 
right to health should prevail.122  
 
On the other side, which is also supported by the WHO, it is believed that these two rights can 
actually live in harmony. WTO has underlined that the international trade treaties have built-in 
flexibilities when dealing with the right to health.123 Nevertheless, it is often disagreed over 
where to draw an appropriate line between patent protection on one hand, and access to essential 
medicines on the other.124 
 
The transitional period for developing countries to apply the TRIPS Agreement provisions 
expired in year 2000, which made the United Nations Human Rights system shift its attention 
to responsibilities stemming from the TRIPS. Resolution 2000/7 on IP Rights and Human 
Rights was approved by the Sub-Commission on the Promotion and Protection of Human 
Rights.125 It is noted in the Resolution 2000/7 that there are real or possible conflicts present 
between the application of the TRIPS Agreement and the realisation of economic, social and 
cultural rights.126 This clash has a major influence on the right to health concerning access to 
patented medications.127 Based on the notion that human rights must be given pre-eminence, 
Sub-Commission set out a plan to analyse IP related issues within the United Nations, in order 
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to address this conflict. As a result, the Commission on Human Rights adopted three 
resolutions: access to medication in the setting of epidemic;128 an examination of TRIPS and 
public health by the High Commissioner for Human Rights129; and an official Statement by the 
CESCR which says that IP linked treaties must be in harmony with the provisions of the 
Covenant.130 
 
Another concern is that some developed countries, such as the United States and also a number 
of European Union countries have signed two-sided treaties called TRIPS-Plus with some 
developing countries, after the adoption of the TRIPS Agreement.131 It is a concern, because 
TRIPS-Plus agreements are much stricter in the sense of IP protection that the original TRIPS 
Agreement requires. Thus, it is no surprise, that the UN High Commissioner for Human Rights 
and the World Health Organisation, based on human rights grounds, have articulated strong 
oppositions to TRIPS-Plus agreements.132 
 
As intellectual property policy has its effect on the direction of innovation in the field of health 
and it also affects the access to medicines, then it has essential impact on the realisation of the 
right to health.133 Depending on the way the intellectual property policy is expressed and 
realised, it can have a positive or a negative role in the society.134 The latter become evident in 
the setting of the world-wide Acquired Immunodeficiency Syndrome (AIDS)/ Human 
Immunodeficiency Virus (HIV) endemic, which depicted the negative aspect of the patent 
protection. 
 
Prices for a three-drug combination of anti-retroviral (ARV) HIV therapy in 2000 from patent-
holding companies exceeded USD $10,000 per person per year, ensuring that treatment could 
not be extended to the vast majority of those living with HIV around the world. Generic 
                                                 
128 Resolution 2001/33 U.N. Comm’n. on Human Rights U.N. Doc. E/CN.4/RES/2001/33 (2001); see also 
Access to Medication in the Context of Pandemics such as HIV/AIDS, Res. 2002/32, U.N. Comm’n. on Human 
Rights; Res 2003/29. 
129 High Commissioner Report. Available at 
http://www2.ohchr.org/english/issues/globalization/trade/docs/5WTOMinisterialCancun.pdf (Accessed 
17.03.18). 
130 Supra n 122, p. 56. 
131 Ibid. p. 59; Generic Resources Action International. TRIPs-plus. Through the Back Door: How Bilateral 
Treaties Impose Much Stronger Rules for IPRs on Life than the WTO. 2001. 
132 Supra n 122, p. 59. 
133 M. El Said and A. Kapczynski. Access to medicines: The role of intellectual property law and policy. –
Working Paper prepared for the Third Meeting of the Technical Advisory Group of the Global Commission on 
HIV and the Law 2011, p. 1. 
134 Ibid.; World Health Organisation. Commission on Intellectual Property Rights, Innovation and Public Health, 
Public Health, Innovation and Intellectual Property Rights: Report of the Commission on Intellectual Property 
Rights, Innovation and Public Health (“CIPIH report”) 2006. 
32 
 
competition led to precipitous price reductions, so that today treatment can be provided for less 
than USD $75 per person per year. This history has contributed to the growing recognition that 
strong medical patents in developing countries undermine access to medicines and sets the 
human right to health in danger.135 
 
Subsequently, it is obvious that the human right to health is weakened through the limitation of 
availability that the patent protection offers to the essential medications, especially in the 
developing countries. Also, it is worth noting that it is not plausible that stronger patent rights 
in developing countries will lead to any substantial offsetting gains in innovation for the 
affected countries. Developing countries represent a very small share of the world’s 
pharmaceutical market, meaning that the marginal added value of stronger patent protection 
will be small, and is unlikely to outweigh the costs to access.136 
 
Many developing states had refused, for human rights concerns, from patenting medicinal 
products before the adoption of the TRIPS Agreement.137 Without patent protection, it would 
have been possible to import generic copies, which would have decreased the prices of 
medicinal products because of the generic rivalry against the patented medicines.138  
 
Nevertheless, this option is not available anymore for TRIPS signatory developing countries 
and although transition period which lasts until 2033 for least developed countries while they 
do not have to apply patents on medicines, then it is only a short-term solution.139 Initially, this 
transition period was until 1 January 2006, then it was extended for pharmaceutical patents until 
1 January 2016, and then again until 1 January 2033.140 
 
TRIPS presents for all WTO signatories the obligation to award patents on medications, while 
establishing a high level of minimum IP protection principles. The flexibilities stemming from 
Articles 7 and 8 of TRIPS that among other things are used for the purpose of safeguarding 
public health, can only be used if they are constant with the provisions of the TRIPS.141 The 
flexibilities stemming from the aforementioned Articles are following: suitable criteria for the 
                                                 
135 Supra n 133, p. 1. 
136 Ibid. 
137 Ibid. 2. 
138 M-H. Bonin and R. Elliott. Patents, International Trade Law and Access to Essential Medicines. – Canadian 
HIV/AIDS Legal Network 2002, pp. 2-3. 
139 WTO. Responding to least developed countries’ special needs in intellectual property. Available at 
https://www.wto.org/english/tratop_e/trips_e/ldc_e.htm (Accessed 17.03.18). 
140 Ibid. 
141 Supra n 2, Article 8. 
33 
 
patentability of medicinal products; effective measures to protect patent quality; and effective 
protections available after patents have been approved.142 The problem is that these flexibilities 
are not used enough and they should be used more, especially in the case of a HIV endemic. 
Even if TRIPS Agreement offers these flexibilities for the developing states to address the 
negative effects arising from the patent protection, then it backfires with the administrative 
burdens associated with these flexibilities.143  
 
Moreover, so-called secondary patents are being used by the medicinal industry, which makes 
it even less inventive.144 These secondary patents can be used on new methods or practise of 
already known ingredients.145 They are regularly effectively used by the medical companies in 
order to prolong or even gain patent protection for their medicines, which makes the secondary 
patents somewhat less creative then primary patents.146  
 
For example. Anti-HIV drug called Efarivenz (from China) had a number of different patents.147 
It is noteworthy that only one patent protected the actual active component. The drug continues 
to be protected by these so-called secondary patents (for example, one on crystallised forms of 
the medicine until 2018 and also certain solid dosage forms until 2019.), while the primary or 
the original patent expired in 2013.148 Efarivenz is not the only one that enjoys these secondary 
patents, there is also the anti-HIV drug called Darunavir. Even more peculiar is that there is 
actually no patent on the active component of the Darunavir. It is solely protected by secondary 
patents, which offer protection to new recipes and mixtures of this medication, thus averting 
generic rivalry of this drug in China until 2023.149 
 
As it can be seen, then there are some points that clash between the medical patents under the 
intellectual property law on the one hand, and right to health under human rights instruments 
on the other one. The main problem is that the intellectual property rights can limit and do limit 
in some cases the availability of the essential medicines, which happens to occur most often in 
underprivileged countries, namely less developed and developing countries. Thus, it is relevant 
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to consider how to address the issue, if possible, so that the intellectual property law and human 
rights instruments could work in harmony, since the both of them are valuable to the society as 
a whole.  
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3 Means to Resolve the Conflict 
 
There is a presumption against conflict in the international law. One way to avoid tension 
between responsibilities is through treaty interpretation.150 According to this, norms are 
interpreted in light of another norm to avoid conflict. For example, where TRIPS gives members 
some leeway to determine the exact way how to follow their obligations or where it contains 
unclear terms that need explanation, the right to health may be used in order to notify policy 
choices and to strike a balance between both obligations.151 
 
In case the treaty interpretation fails, then it is clear that a genuine conflict exists. If that 
happens, then a series of conflict resolution techniques are available, such as the lex superior 
derogat legi inferior, lex posterior derogat legi priori, and lex specialis derogat legi generali. 
The relevance of the latter two methods to actually resolve a conflict here is dubious. The lex 
posterior rule adopts that the contradictory norms originate from the same legislator, which at 
the moment is not the case, and as such this rule is difficult to apply.152 The lex specialis rule is 
only appropriate in a situation of conflict amid special and general international law. However, 
international human rights law and WTO law are subsystems of general international law. 
Therefore, on this matter, the lex posterior and lex specialis rules are unproductive conflict 
resolution techniques. 
 
The best way to resolve the conflict between TRIPS and the right to health would be to form 
that one of the two norms has a superior position in the international law. That is precisely what 
some human rights bodies and analysts have reasoned for. 
 
International law distinguishes that some norms are superior to others. Jus cogens or 
peremptory norms are norms “accepted and recognised by the international community of states 
as a whole as a norm from which no derogation is permitted”.153 Generally acknowledged 
examples include the prohibition of genocide, slavery, torture, racial discrimination and crimes 
against humanity. Others have added to this list (the prohibition of gross violations of) the right 
                                                 
150 J. Pauwelyn. Conflict of Norms in Public International Law. How WTO Law Relates to Other Rules of 
International Law. New York: Cambridge University Press 2003, p. 244. 
151 X. Seuba. Mainstreaming the TRIPS and human rights interactions. – C.M. Correa. Research handbook on 
the protection of intellectual property under WTO rules. 1 Intellectual property in the WTO. Cheltenham: 
Edward Elgar 2010, p. 201. 
152 International Law Commission (2006) Fragmentation of international law: difficulties arising from the 
diversification and expansion of international law. Report of the Study Group of the International Law 
Commission. Finalised by Martti Koskenniemi. UN Doc A/CN.4/L.682 para. 234 
153 United Nations. Vienna Convention on the Law of Treaties. 1969, Article 53. 
36 
 
to life, dignity and bodily integrity.154 The Committee on Economic, Social and Cultural Rights 
finds that the provision of medicines is part of the minimum core content of the right to health 
and, thus, a non-derogable obligation.155 International practice, though, proposes a narrow 
approach to the categorisation of jus cogens norms.156 There is no international consent to 
extend jus cogens status past the prohibitions mentioned above. Furthermore, it is rather 
uncertain whether the resolve by the CESCR that the core content of a right is non-derogable 
would lead to the assumption that such core content is consequently a prioritised norm under 
international law. The ICESCR itself does not officially prioritise certain elements of a right 
above others, nor does it comprise a provision comparable to the ICCPR disallowing 
derogations from the rights preserved in the ICESCR. Instead, it provides for the option to 
enforce restrictions (Article 4 ICESCR). Additionally, the Committee’s General Comment No. 
14 is not legally binding. Accordingly, there is no proof to suggest that the present list of 
acknowledged peremptory norms includes the right to health or a right of access to essential or 
even life-saving medicines.157 
 
What is more, it has been argued that human rights as a production of United Nation’s Charter 
obligations would enjoy pre-eminence on the basis of Article 103 of the UN Charter.158 Article 
103 states that “in the event of a conflict between the obligations of the members of the United 
Nations under the present Charter and their obligations under any other international agreement, 
their obligations under the present Charter shall prevail”. Obligations stemming from human 
rights treaties implemented within the UN framework, e.g. ICESCR, are then considered to be 
duties under the Charter, predominantly under Articles 55 and 56, and would thus prevail over 
WTO responsibilities. However, this interpretation of Article 103 is not plausible. Article 103 
gives predominance to those obligations specifically stated in the UN Charter and originating 
from obligatory decisions by UN bodies, most especially Security Council resolutions adopted 
under Chapter VII, but not to human rights treaty duties or non-binding resolutions accepted by 
UN human rights bodies.159 
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As it is seen above, international law prioritises certain interests over others. Similar is accurate 
for the CESCR’s approach that prioritises certain elements of rights as non-derogable 
obligations. Nevertheless, there is no proof that international law accepts human rights norms, 
except jus cogens, as higher norms than other international law norms.160 There is no evidence 
that the whole international community recognizes the right to health as a peremptory norm. 
Therefore, lex superior rule cannot be used to resolve a conflict between the right to health and 
patents. Tension must be resolved through treaty interpretation in that case. 
 
The main way, consequently, in which to evade a conflict between TRIPS and ICESCR is in 
interpreting the TRIPS Agreement in a way which is favourable to endorsing and protecting the 
right to health and access to medicines.161 
 
International human rights law is not directly applicable within the WTO dispute settlement 
system. However, the WTO Appellate Body has confirmed that WTO law cannot be read in 
clinical separation from public international law and also that WTO law should be interpreted 
in accordance with the customary rules of treaty interpretation, meaning Article 31 and 32 
VCLT.162 The WTO adjudicative bodies may consequently take account of human rights norms 
when interpreting TRIPS, yet some care is required when comparing an international treaty to 
which not all WTO members are a party to.163 What is more, according to the WTO, the TRIPS 
Agreement promotes principles which are vital for the realisation of human rights and aims at 
striking a suitable balance between IP protection and human rights norms.164 This is also in 
accordance with the Doha Declaration on TRIPS and Public Health, which is clear in the way 
in which members should settle any conflict between IPRs and public health. Paragraph 4 of 
Doha Declaration states that: 
 
“The TRIPS Agreement does not and should not prevent Members from taking measures to 
protect public health. Accordingly, while reiterating our commitment to the TRIPS Agreement, 
we affirm that the Agreement can and should be interpreted and implemented in a manner 
                                                 
160 A. Hallo de Wolf. Human rights and the regulation of privatised essential services. – 60 Netherlands 
International Law Review 2013, pp. 199-200. 
161 Supra n 117, pp. 293-294. 
162 WTO Appellate Body Report, United States—Standard for Reformulated and Conventional Gasoline, 
adopted 20 May 1996, WT/DS2/AB/R, p. 17. 
163 WTO Appellate Body Report, European Communities and Certain Member States—Measures Affecting 
Trade in Large Civil Aircraft, adopted 1 June 2011, WT/DS316/AB/R, para. 844. 
164 CESCR. Protection of Intellectual Property under the TRIPS Agreement. Background Paper Submitted by the 
Secretariat of the WTO. UN Doc. E/C.12/2000/18, paras. 13 et seq. 
38 
 
supportive of WTO Members’ right to protect public health and, in particular, to promote access 
to medicines for all. 
 
In this connection, we reaffirm the right of WTO Members to use, to the full, the provisions in 
the TRIPS Agreement, which provide flexibility for this purpose.” 
 
Although indirectly, it is referred here by the Doha Declaration to the promotion and protection 
of human rights.165 For example, the Special Rapporteur on the right to health stated that “in 
this way, the Declaration reflects human rights perspectives, especially the right to health and 
the right to enjoy the benefits of scientific progress”.166 
 
Striking a balance between public and private interests is also a field familiar to IP laws. For 
example, the monopoly position granted to a patent holder is for a limited time and non-
renewable, intended to provide creators with the possibility to recoup research and development 
expenses; in return creators must reveal their inventions, which has been an essential element 
of patent law since its beginning. Thus, patents aim to provide access to the information in the 
short term and access to the actual (patented) creation, and future creations, in the long term. 
Accordingly, the High Commissioner discovered a degree of compatibility between Article 15 
and traditional intellectual property systems, yet suggested that the main problem is ‘where to 
strike the right balance’.167 
 
Special Rapporteur Anand Grover provided a report to the Human Rights Council in 2009 
analysing the effect of the TRIPS Agreement on access to reasonably priced medicines.168 He 
stated that “from a right to health perspective, developing countries and least developed 
countries should be enabled to use TRIPS flexibilities”.169 He mentioned the following 
flexibility methods which members should include in their national laws: make full use of the 
transition periods; define the criteria of patentability; issue compulsory licences and provide for 
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government use; adopt the international exhaustion principle to facilitate parallel importation; 
create limited exceptions to patent rights; and allow for opposition and revocation procedures. 
 
India, for example, is a country that has taken full advantage of the transition period by allowing 
product patent protection only in 2005 upon the expiration of its TRIPS deadline.170 Until that 
time, it did not permit product patents to be granted to medicines. Accordingly, it was able to 
develop a sturdy generic pharmaceutical industry.171 
 
The TRIPS Agreement forces members to enforce its provisions, nevertheless it also states that 
“members shall be free to determine the appropriate method of implementing the provisions of 
this Agreement within their own legal system and practice”.172 Therefore, developing members 
have a degree of freedom when executing the TRIPS provisions, provided that they stay within 
the limitations of TRIPS. Article 27.1 of the TRIPS Agreement lays down the conditions with 
regard to patentable subject matter and conditions for patentability. Although it is not possible 
to exclude medicines from patent protection anymore, Article 27.1 does not outline the notions 
of novelty or inventiveness and, consequently, leaves substantial flexibility for WTO members 
to resolve the way how to implement and interpret this responsibility.173 
 
For instance, India’s definition of “inventive step” is exceptional in that it is stricter than in 
many other countries as it necessitates an invention to include a “technical advance”, “economic 
significance” or both, in addition to the element that the invention is not obvious to a person 
skilled in the art.174 
 
What is more, India also introduced an exclusive section about patentable subject matter. 
Section 3(d) is one of the most debated amendments made to the Indian Patents Act. It was 
implemented due to the threat of so-called “evergreening”, which refers to the practice of the 
pharmaceutical industry to effectively extend the term of protection for patented 
pharmaceuticals by obtaining related patents for minor modifications made to the original 
product, new delivery systems for the pharmaceuticals, or new uses of the pharmaceutical. A 
problem also acknowledged by the Indian Technical Expert Group on Patent Law Issues that 
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stated that ‘every effort must be made to provide drugs at affordable prices to the people of 
India’.175 Firstly, section 3(d) forbids patents for derivative, apart from if it can be shown that 
they provide a considerably enhanced efficiency. It is a provision that is exceptional and does 
not exist in any other patent regime.176 The “evergreening” of pharmaceutical patents is made 
virtually impossible. In addition, section 3(d) encompasses a complete exception to 
patentability by declaring that the mere discovery of any new property of, or new use for, a 
known substance is not considered patentable.177 India’s obstructive position on this subject 
differs with the tolerant approach in the United States and Europe in patenting subsequent 
medical usages of known pharmaceuticals.178 
 
India deliberately implemented TRIPS in a way which seeks to strike a balance between 
minimum standards of TRIPS and promoting right to health by providing access to medicines. 
However, this approach is not favoured by everyone and has received disapproval and 
criticism.179 Novartis confronted the constitutionality and TRIPS compatibility of section 3(d) 
when the Indian Patent Office declined to grant a patent for its cancer medicine, Gleevec.180 
The case was contested up to the Indian Supreme Court, which supported the constitutionality 
of the provision.181 The Supreme Court’s judgment was interpreted as a victory for patients’ 
right of access to vital medicines by civil society.182 
 
3.1 Compulsory Licensing and Doha Declaration 
 
A useful tool for balancing access to medicines and patent protection is found in the Article 31 
TRIPS183 dealing with the compulsory licensing. The use of this measure occurs when a 
relevant body gives its permission for a third party to manufacture the patented product or 
procedure without the permission of the actual patent owner. CL can be used to increase generic 
production, importation and/or domestic competition and therefore lower the medicine prices. 
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Of course, there is a possibility for patent holder to grant a third party a voluntary licence to 
produce or use its patented product or process. However, pharmaceutical corporations do not 
always favour this kind of approach which makes the granting of a CL, or merely the threat of 
it, a useful tool. It is up to the members to decide which grounds a CL is granted upon. 
 
The agreement allows compulsory licensing as part of the agreement’s overall attempt to strike 
a balance between endorsing access to already obtainable medications and promoting research 
and development into new drugs. But the term “compulsory licensing” does not appear in the 
TRIPS Agreement. Instead, the phrase “other use without authorization of the right holder” 
appears in the title of Article 31.184 Compulsory licensing is only part of this since “other use” 
includes use by governments for their own purposes. 
 
Compulsory licensing and government use of a patent without the authorisation of its owner 
can only be done under a number of conditions in order to defend the reasonable interests of 
the current patent owner. For example: Normally, the person or company looking to obtain a 
compulsory licence must have first made an effort, although unsuccessfully, to obtain a 
voluntary licence from the right holder on reasonable commercial terms — Article 31b.185 If a 
compulsory licence is issued, adequate remuneration must still be paid to the patent holder — 
Article 31h.186 However, for “national emergencies”, “other circumstances of extreme urgency” 
or “public non-commercial use” (or “government use”) or anti-competitive practices, there is 
no need to try for a voluntary licence — Article 31b.187 Compulsory licensing must meet certain 
additional requirements. In particular, it cannot be given exclusively to licensees (e.g. the 
patent-holder can continue to produce), and usually it must be granted mainly to supply the 
domestic market. 
 
It is not explicitly stated by the TRIPS Agreement which reasons provide excuse for using CL. 
In Article 31188, it does mention national emergencies, other circumstances of extreme urgency 
and anti-competitive practices — but only as grounds when some of the normal requirements 
for compulsory licensing do not apply, such as the need to try for a voluntary licence first. 
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A compulsory license limits the rights of the patent holder, but does not take those rights away. 
TRIPS therefore specifies the conditions that need to be applied when countries want to grant 
a compulsory license. An important condition is that each case shall be considered individually. 
Also, in general, efforts should first be made to obtain a license from the patent holder (a so-
called voluntary license), on reasonable terms. What is considered “reasonable” depends on 
national (case) law.189 
 
Patent owner is encouraged by the CL provisions to behave correctly. CL prevents the patent 
owners from misusing the monopoly rights granted to them by giving the patent owner a sign 
that when the patent rights are abused or the product is made non-available, then a third party 
could be given a permission to use the invention. CL is a necessary element in IPR law because 
it has a serious impact on the actual behaviour of the patent owner. Thus, to makes sure that 
this system is used properly, the national legislation has to set the ground and conditions for it 
in a careful manner, which should include its use for reasons related to public health.190 
 
According to Doha Declaration the signatory states to TRIPS should be able to take the 
necessary steps to ensure the protection of public health and also be able to use the flexibilities 
provided by TRIPS in their full potential. The use of compulsory licenses should not be limited 
to only if there is a national emergency or any other case of great danger. The States should be 
able to decide the conditions that will permit the use of CL. It was Doha Declaration that 
extended the transition period in connection with the patents on drugs in least developed 
countries until 2016. Then the Council Decision prolonged the transition period until January 
2033. Until that time the TRIPS Agreement will not apply to medicinal products in LDCs.191 
The LDCs can still make a choice whether they want to implement patent protection for 
medicines before the deadline of 2033.192 
 
As CL is a mean to permit for the production and provident to the domestic market of the State 
that issues a compulsory license, then the Doha Declaration did not address the problem in 
connection with the LDCs with deficient or no engineering capability in the medicinal 
                                                 
189 The TRIPs Agreement and Pharmaceuticals. Report of an ASEAN Workshop on the TRIPs Agreement and 
its Impact on Pharmaceuticals. Jakarta, 2-4 May 2000. 
190 Ibid. 
191 WTO. WTO members agree to extend drug patent exemption for poorest members. Available at 
https://www.wto.org/english/news_e/news15_e/trip_06nov15_e.htm (Accessed 17.03.18). 
192 Ibid. 
43 
 
division.193 This problem was addressed by the 2003 waiver Decision194, which offered an 
answer for the unsettled matter and allowed for CL to be distributed by exporting countries to 
qualified countries that do not have the necessary manufacturing capabilities in the medicinal 
area. 
 
3.1.1 Integrating 2003 Decision into TRIPS 
 
As mentioned above, the 2003 Decision addressed the problem that was left unsettled by the 
Doha Declaration, specifically the problem of the developing or less developed countries with 
no capacity to produce the necessary medicine on their own. The answer provided by the 2003 
Decision was that the Article 31(f) of the TRIPS was waived so that countries that have the 
capacity to produce medicines could export their inexpensive medicinal generic products 
similar to patented products under compulsory licenses also to the less developed and 
developing countries that have no engineering capability on their own.195 This means that 
Article 31(f), which hinders the export of medicines, since it only permits to distribute 
medicines inside the country that issued a CL, was cast aside by the 2003 waiver Decision to 
offer an answer to the impoverished countries in order to receive inexpensive generic 
medications that are similar to patented products from capable countries.196 
 
Thus, the members of the WTO included on the 6th of December the “waiver” from the 2003 
Decision in the TRIPS as a perpetual provision by accepting the alteration of the TRIPS 
Agreement.197 Nonetheless, in order for the amendment to take effect and be officially 
incorporated into the TRIPS Agreement, the requirement was that at least two thirds of the 
members of the WTO had ratified the relevant provision. This was not achieved until 23rd of 
January 2017, when the needed quantity of States had finally ratified the innovative 
provisions.198 It should be noted that the original deadline to do that was 1st of December 
2007.199 However, even if two thirds of the members of WTO have ratified the provision, then 
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the new provisions apply only in the countries that recognised the amendment, thereby 
replacing the 2003 Decision. Because of this, by the decision of 30 November 2017 of the 
General Council, the period for acceptances of the Amendment by the WTO Members was 
extended for the sixth time, until the 31st of December 2019 to enable for the rest of the 
Members to accept the amendment.200  
 
It is required for the members of the WTO, who are planning to export using the “waiver” from 
the 2003 Decision, and indirectly the newly incorporated Article 31bis of the TRIPS, to alter 
their domestic legislation also, so they could actually make use of the amendment of the TRIPS 
Agreement and the new provisions in it. TRIPS Council has been officially informed, so far, by 
a rather small number of the members of the WTO, who have made the relevant changes in 
their domestic legislation, so that they could export medicinal products to countries who need 
them by using the new provisions applied to compulsory license, for example Canada, EU, 
India and Norway.201 EU Member States have affirmed that they have officially recognised the 
alterations in TRIPS and affirmed that it will apply to the European Union as a whole.202 
 
It is worth mentioning, that some States have proclaimed from the beginning, that the system 
is not planned to be used to import203, also a quantity of States have declared to plan to use this 
system in cases of crises or other tremendously crucial circumstances.204 
 
By amending the TRIPS Agreement and adding the Article 31bis, the 2003 Decision, which 
contained the “waiver”, was finally integrated with the TRIPS. This was done to address the 
issue of the fact that the compulsory license did not provide any help to countries that have 
limited capacity to produce essential medicines on their own, usually these being less developed 
and developing countries of the WTO. 
 
Article 31bis consists of five paragraphs, which of four are relevant to the study. First one 
allows for the developed countries which contain medical patents to hand out CL for the 
production and exportation of the needed drugs to the qualified countries which have no 
capacity to produce these drugs on their own. The second paragraph deals with compensation 
                                                 
200 WTO. Amendment of the TRIPS Agreement. Available at 
https://www.wto.org/english/tratop_e/trips_e/amendment_e.htm (Accessed 17.03.18). 
201 Supra n 197. 
202 Supra n 200. 
203 Supra n 197. 
204 Ibid. 
45 
 
to the current patent owner and it says that in a case when CL is handed out in the exporting 
State, then the compensation that considers the financial worth to the country the drug is 
exported, should be paid to the patent owner. This compensation does not have to be paid if the 
same product is already allowed under CL in the country that receives the drug from the 
exporting State. According to the third paragraph, the responsibility under Article 31(f) will not 
apply for the importing Member, if a developing or a less developed WTO Member State is at 
the same time a part of a local trade treaty. It only applies to the degree required to permit the 
medicinal goods manufactured or distributed to the relevant country under a CL to be 
transferred to other LDCs or developing states that are part of the local trade treaty and are 
troubled by the similar health issue. In paragraph four it is specified that no challenges should 
be taken by WTO Member States against any measures that will be afterwards taken in 
conformity with the TRIPS Agreement’s Article 31bis and its Annex.205 
 
3.1.2 About the Amendment 
 
The Sixth WTO Ministerial Conference permitted the proposal to transform the Waiver 
Decision into a permanent alteration to the TRIPS Agreement206. The alteration could be 
formally adopted only after acceptance by two-thirds of the WTO members. 
 
The two-thirds threshold for official adoption of the alteration was recently met and the 
amendment entered into force on 23 January 2017. The new Article 31bis allows developing 
and LDCs facing public health problems and lacking drug manufacturing capacity to import 
such drugs from third-country producers under compulsory licensing measures. 
 
This flexibility, nevertheless, is not unconditional. Abundant conditions are imposed by Article 
31bis (and the related Annex) and the derogation to Article 31(f) applies only “to the extent 
necessary to enable a medicinal product produced or imported under a compulsory licence in 
that member to be exported to the markets of those other developing or LDC parties to the local 
trade arrangement that share the health problem in question”207. Only eligible countries, either 
LDCs or developing countries with insufficient or no drug manufacturing capacity, are entitled 
to use the waiver208. 
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Some of the noteworthy conditions attached to Article 31bis are as follows: 
1. Before applying to the administration for a compulsory licence, the generic drug 
engineering business in the exporting country is required to negotiate a voluntary license 
with the patent holders. 
2. The importing member states are required to provide a general announcement of intent. 
The qualified importing country must provide certain specified information to the 
Council, for example the specific name of the required medication and the expected 
amount of the medication. The announcement of intent is, nevertheless, not compulsory 
for LDCs. 
3. The generic drug engineering firm, in the exporting country, is required to apply for two 
compulsory licenses: one in the exporting country, or home country, and one in the 
importing country, if the needed medication is also patented in the importing state. 
4. The exporting country must also let the Council know about the grant of the compulsory 
license; the announcement must encompass the following mandatory information: the 
name and address of the licensee, the products, the quantity granted, the state to which 
the product is to be delivered, the period of the license, and the address of the website 
where the provider will post the data mentioned in paragraph 2(b)(iii) of the Annex. 
5. There is an additional requirement for the exporting country to uphold a distinction 
(unique shape, colour, size or characteristic outer wrapping or even a dissimilar trade 
mark) between the generics factory-made for national use and the generics engineered 
for export. The justification for this distinction is to prevent abuse of Article 31bis. 
 
The waiver in question is seen as a rare negotiation victory for third world countries. 
Unfortunately, the modification is not likely to make the desired real-world impact because of 
the overly burdensome bureaucracies that supplement it. The requirement of negotiating a 
voluntary license is a supplementary encumbrance that is likely to cause postponement to timely 
access to the immediately needed medication. Given this encumbrance, the generic engineering 
businesses may choose not to partake in the procedure.209 
 
Additionally, the compulsory licenses required for using the waiver flexibility are required to 
be granted only for a prearranged time period. The grant of a compulsory license, within the 
overall system of the TRIPS Agreement, itself includes numerous time-consuming legal, 
administrative and procedural requirements. These may discourage the generic manufacturing 
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businesses from pursuing dual compulsory licenses. The limited length of the licenses may 
further aggravate this consequence. The disturbance to renew the compulsory license for 
restricted periods seems to be an administrative encumbrance, as the issue of admittance to the 
necessary medication is probable to remain sturdy as long as the medication patent is in 
effect.210 
 
Lastly, the limit on the amount of medications that can be mass-produced for export under 
Article 31bis appears to be irrational. Giving a clear estimation of the amount of the necessary 
medication, particularly in the case of epidemics and endemics, is almost unmanageable. If the 
requirement surpasses the predicted quantity, the burdensome endorsement procedure needs to 
be repeated for the acquisition of more medications. The supplementary encumbrance of 
compliance with the burdensome anti-diversion measures, which not only add to the price of 
manufacture but can also lead to lawsuit, may further dishearten generic drug producers from 
partaking in the regime.211 
 
The waiver flexibility was envisioned to provide a speedy resolution to the problem of 
inexpensive admittance to indispensable medications, particularly in emergency circumstances. 
As argued above, the effectiveness of Article 31bis is expected to be hindered by the tiresome 
and needlessly burdensome endorsement procedures. Technical details and bureaucracies may 
dishearten the generic drug producers from using this provision.212 
 
The use of this flexibility also requires specific changes to domestic patent laws. LDCs 
seriously lack technical know-how in intellectual property and most of them have failed to 
incorporate this difficult provision in their domestic patent laws. As of February 2017, the 
waiver flexibility has been used only one time. This establishes that it did not offer a practical 
resolution to the problem emphasised in Paragraph 6 of the Doha Declaration. Making this 
flexibility a long-lasting resolution, without making changes to address the above-mentioned 
distresses, is doubtful to have any considerable real-world importance. Inexpensive admittance 
to indispensable medications may remain a dream for impoverished nations despite altering the 
TRIPS to explicitly address this problem.213 
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3.2 Integration of TRIPS in the EU 
 
It has been established above that because of the world-wide applicability of both human rights 
and intellectual property rights related provisions, the access to patented medications and the 
right to health is governed by the international law. Because of this, the Institutions of the 
European Union have integrated 2003 Decision by adopting two Regulations. In order to 
integrate the “waiver” from 2003 Decision into the laws of the European Union, EU set up an 
extensive basis to make sure that the poverty is decreased in connection with prices on different 
essential medicines.214 The Regulations adopted belonged to the broader action strategy of the 
European Commission in 2001, which dealt with TB, malaria and HIV/AIDS.215 First 
regulation is to avoid trade diversion into the EU of certain key medicines (Council Regulation 
(EC) 953/2003)216 and the other one is on compulsory licensing of patent relating to the 
manufacture of pharmaceutical products for export to countries with public health problems 
(Regulation (EC) No. 816/2006).217 
 
3.2.1 EU Regulation to Avoid Trade Diversion of Key Medicines 
 
A legislative act was suggested by the Commission to European Council and to the Parliament 
in 2001. The purpose of this act was to set up a global tiered pricing system for the most 
impoverished developing countries of the most important medications which prevent, diagnose 
and treat TB, malaria and HIV/AIDS and other similar diseases.218 The idea was to set effective 
safeguards in place to prevent the spread of generic or cheaper medicines to other markets.219 
The idea of the Regulation 953/2003 was to make the producers of medications to increase the 
obtainability of drugs, which can be achieved by lowering the prices in developing states, and 
to also enhance the number of drugs being exported to the relevant countries, with that in mind 
that these medications would stay in the markets they were actually meant for.220 
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Therefore, the Regulation stressed that the necessary cheap drugs which were meant for 
underprivileged markets would not leave those markets, which could harm the price of these 
drugs in developed countries. It also recognised for enhanced action on TB, malaria and 
HIV/AIDS.221 It should be noted that this Regulation in connection with pharmaceuticals did 
not extend to drugs carried by travellers meant for non-commercial individual use within the 
allowed limits set up by the customs duty.222 
 
Both generic drugs and patented drugs were governed by the provisions of the Regulation, 
which means that both of them are valid for registration.223 Annex II to the Regulation provided 
a list of states of destination.224 
 
It was prohibited by the Regulation, as a general responsibility, to import tiered priced 
medications into the European Union with the objective of releasing them into free circulation, 
repetitive export, putting them under suspensive processes or putting them in a free warehouse 
or free zone.225 Nevertheless, there were exceptions for some fixed circumstances, however, 
one has to keep in mind that safeguards were in place so that the medication would reach the 
destination that were provided in the Annex II.226 
 
Commission encompassed the Regulation in its regulatory fitness and performance programme 
of 2013 (REFIT).227 Nonetheless, Regulation’s mechanism has not been used much so far. For 
example, it was used by GlaxoSmithKline (GSK). After GSK had used this mechanism and 
registered its medicines under the relevant instrument, the outcome was a progressive, but 
considerable deterioration of the sale volumes.228 Because of this, it was found necessary to 
assess the functioning and influence of the incident in order to find out why the Regulation was 
not used as much.229 
 
In July 2015, the assessment of the Regulation finally occurred. The assessment included five 
aspects (originally four, but one was added). These were effectiveness, efficiency, coherence, 
relevance, and the additional one: against the REFIT purposes, which takes into account 
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whether it is suitable for objective, if the purpose can be served at lowest prices, and its 
prospective to be simplified.230 
 
On the first criteria, effectiveness, there was no evidence to suggest that the registered products 
according to Regulation found their way back to European Union, this took into account the 
fact that supplementary measures were taken by GSK for the purpose to avert the product 
diversion. It was additionally found, among other things, that the price drop happened, which 
was not naturally because of the Regulation’s effect; the stock of HIV/AIDS medications by 
the GSK was amplified to targeted States because of the Regulation, and because the 
corporation gave licenses to generic manufacturers, then more GSK’s medications were 
supplied, which resulted in GSK’s meaningful contribution to curing HIV.231 
 
On the second criteria, efficiency, the Commission was found, in operating the system, to only 
sustain administrative expenses. Extra costs were incurred solely by the pharmaceutical 
company GSK, which stemmed from addition of the logo and registration of its products 
through the Commission. The additional profits from the regulation were: the prices of drugs 
which were sold to developing states became more transparent; because of the decrease of need 
for GSK to implement other more costly processes to refrain from diversion of products to other 
markets, there was a counterweighing of expenses. It was established that European Union’s 
expenses were in balance with the Regulation’s profits.232 
 
In regards, with the third criteria, coherence, it was established that the Regulation fitted with 
other European Union strategies and it is harmonious with European Union’s responsibilities 
in the international level of public health and progress. 
On relevance, which is the fourth criteria, it is suggested that the Regulation is not that relevant 
any more, since there is a low chance of the TB, malaria and HIV/AIDS medications to be 
diverted. Nevertheless, tiered pricing is still considered to present an important contribution  
Nevertheless, it has been recognised that tiered pricing still presents an important influence to 
the over-all admittance to medications.233 
 
All in all, it was determined by the evaluation, according to the four key aspects, that the 
Regulation is of restricted significance and has no noteworthy net profits. Nevertheless, the 
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prices of upholding it are correspondingly limited and, most notably, reasonable. Additionally, 
evaluation against the REFIT purposes revealed that making the drugs accessible in the 
underprivileged developing states is pertinent, there is significance in the tiered pricing which 
is supported by the European Union through the Regulation. Thus, the elimination of the 
Regulation could send out a false signal that European Union does not support the notion of 
tiered pricing, because it was thanks to the Regulation that sent the businesses a message about 
this system. Consequently, it can be said that there is no harm in upholding the Regulation, 
since it is not that burdensome and costly.234 
 
In 2016 the Regulation of 953/2003 was repealed and replaced by the Regulation 2016/793. 
This was done because the Regulation 953/2003 had been substantially amended several times, 
so in the interests of clarity and rationality, the Regulation was codified by Regulation 
2016/793.235 Since 2016/793 is a codification of the 953/2003, then the essence of the initial 
Regulation remains in force. 
 
3.2.2 EU Regulation on Compulsory Licensing 
 
Members of the WTO were granted by the Doha Declaration the chance to hand out compulsory 
licenses as well as the liberty to decide on their own which grounds satisfy the approval of this 
license.236 For the purpose of helping out the members of the WTO who are not capable of 
producing their own medications, the WTO General Council approved after the Doha 
Declaration a Decision in 2003. In this Decision lies an opportunity to set aside some of the 
obligations that the TRIPS Agreement establishes in connection with the compulsory 
licenses.237 
 
In 2006 European Union the legislation of EU was complemented with the purpose of 
complying and at the same time implementing the Decision of 2003.238 This was done by the 
European Parliament and Council by approving the Regulation 816/2006 which deals with 
enabling the lifesaving medication to be exported to states that cannot produce them on their 
own under compulsory licensing. It can be said that the regulation was one of the measures of 
the European action plan which was aimed to deal with less developed and developing countries 
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that are struggling with public health issues.239 With the purpose of reaching identical 
conditions in the European Union market and to avoid competition’s distortion, the regulation 
of compulsory licenses that enables medicines’ production and export, was welcomed.240 This 
Regulation helps in a broader sense to deal with the issue of availability of inexpensive 
medications in the less developed and developing countries.  
 
Similarly to Regulation 2016/793, the Regulation 816/2006 contains the same principle of 
disallowing the medicinal merchandise that was produced and exported under the compulsory 
license to the country of low capacity of production, to flow back to the European Union so that 
this product could be released for free circulation.241 Regulation 816/2006 also pays in mind, 
in order to avoid facilitating overproduction and possible diversion of products, the parallel 
applications indicated by the applicant and already present compulsory licenses for the same 
goods and states.242 
 
Regulation’s key points are the following: 
• The importing countries eligible to benefit from the scheme are: 
o the world's least developed countries; 
o those which have informed the World Trade Organization of their intention to 
do so; 
o those listed in the OECD development assistance committee list of low-income 
countries. 
• The importing countries must confirm they will use the scheme for public-health 
purposes, not for industrial or commercial objectives. 
• Any person who has failed to secure authorisation from the patent holder may submit a 
request for a compulsory licence to the relevant national authority. 
• They must provide personal details, information on the product, the amount they intend 
to produce and the destination countries. 
• This must be backed by a specific request from the country concerned, a non-
governmental organisation or a United Nations body. 
• The relevant national authority in the EU informs the rights-holder and verifies the 
validity of the request before taking a decision. 
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• Conditions attached to the compulsory licence determine the quantities involved and 
duration of the concession. Products made under licence must be clearly identifiable by 
specific labelling or marking. 
• Products manufactured under a compulsory licence may not be reimported and sold in 
the EU. Any suspected of breaking the law may, initially, be detained for 10 days and 
ultimately seized. 
• A licensee failing to respect the conditions of a compulsory licence may find it reviewed 
and even terminated.243 
 
The Regulation establishes a procedure for companies in the European Union wishing to 
manufacture generic medicines for use in the developing world to apply for a compulsory 
licence from a patent holder, which allows their manufacture.244 Thus, it is up for the domestic 
authority (Commission must be notified of the chosen relevant body by the State)245 to decide 
who to hand out compulsory licenses according to its domestic patent related legislation. 
 
This system allows to import into the following countries: any least-developed country 
appearing as such in the United Nations list; any member of the WTO, other than the least-
developed country members referred to in the previous point, that has made a notification to 
the Council for TRIPS of its intention to use the system as an importer, including whether it 
will use the system in whole or in a limited way; any country that is not a member of the WTO, 
but is listed in the OECD Development Assistance Committee's list of low-income countries 
with a GNP per capita of less than 745 US dollars, and has made a notification to the 
Commission of its intention to use the system as an importer, including whether it will use the 
system in whole or in a limited way. 
However, any WTO member that has made a declaration to the WTO that it will not use the 
system as an importing WTO member is not an eligible importing country.246 
 
Article 5 deals with the extension to least-developed and developing countries which are not 
members of the WTO. By this article the relevant country will notify the Commission and state 
that it has public health issues and will not use this measure for commercial purposes.247 
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According to Article 6 of the Regulation, anyone can file their request to receive a CL to a 
relevant body in the country or countries that allow patents or other protections. It is further 
required for the applicant that submits CL requests in multiple countries for the identical 
merchandise, to mention in every application of this intention with the detailed amounts of the 
product and the countries that the product is going to be imported to.248 
 
Article 8 of the Regulation deals with the verification. This Article requires that the competent 
authority shall verify that each importing country cited in the application which is a WTO 
member has made a notification to the WTO pursuant to the Decision, or each importing 
country cited in the application which is not a WTO member has made a notification to the 
Commission pursuant to this Regulation in respect of each of the products covered by the 
application that: 
• stipulates the names and probable amounts of the merchandise desired; 
• except the importing state is a LDC, proves that the country is not capable the produce 
the necessary pharmaceutical on their own according to the Decision’s Annex; 
• proves that in case there is patent protection on the medication in the country of 
destination, then the relevant authority in that country has already issued a compulsory 
license or is planning to do it in the near future, so that the merchandise could be 
imported.249 
 
Article 9 is about prior negotiation. By this article, it is required by the applicant to provide 
evidence to the authority about the fact that the applicant has negotiated with the current patent 
holder and these negotiations have failed. This cannot be done until a 30 day period has passed 
until the application for the CL. Nevertheless, this requirement can be ignored if a national 
emergency or something similar occurs, also if it is used non-commercially for the public 
purposes by following the Article 31(b) of TRIPS.250 
 
Article 10 deals with compulsory license conditions. According to this Article, the license 
granted is generally non-assignable and non-exclusive. It is required not to produce more under 
the license that the importing country actually needs, while also keeping in mind the production 
of similar goods under the CL in other places. There has to be a set deadline for the license. The 
product can strictly be sold only in the market it is meant for and should not be sold in other 
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markets, however an exception could allow to export from the imported country to a place that 
shares the same health problem, if necessary. There are a number of requirements for the 
packaging of the product manufactured under the CL, for example, it has to be clear that the 
product is subject to compulsory licensing. Before, distribution to the relevant country, the 
license holder will also have to post some information on the website (for example, quantity of 
the product), of which address has to be communicated to the relevant body. If it happens that 
the product is also patented in the country that it is distributed, then CL must be granted in that 
country before the import. It is possible for the relevant authority to check the documentation 
held by the CL holder to check whether the strict requirements stemming from the legislation 
is being followed. The license holder is the one responsible that the patent owner is being 
compensated.251 
 
The relevant body can choose to terminate the license under Article 16, if the license holder is 
not following the proper conditions. It is up to the competent authority to analyse and decide if 
the Regulation respected by the license holder, which can be done at the request of the patent 
holder or the licensee. When the license is terminated, then it can be that the licensee has to 
redirect on his own expenses the product to the places that need it or dispose of it, which is 
orchestrated by the competent authority. If it happens that the exported amount of medicine 
falls short of the needs of the country with the health problem, then the competent authority can 
modify the license to allow more of the product to be produced and exported. This application 
is then processed in a quicker and simpler manner.252 
 
Additionally, Article 17 deals with the appeals against the competent authority.253 Article 18 is 
about safety and efficacy of medicinal products.254 And finally, Article 19 is about review, 
which requires for the Commission to file a report to the relevant bodies in regards of the 
functioning of the Regulation at hand with proposals (if any) for modifying the Regulation.255 
 
It can be seen in the example of the Regulation in question, that the European Union has taken 
the incorporation of the 2003 Decision into its legislation quite seriously. This is because they 
have set in place a legal framework with strict provisions to address the issue of medicine 
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availability. Thus, EU is providing its contribution in improving the health in developing or less 
developed countries that have no capacity to produce essential medications on their own.  
57 
 
Conclusion 
 
The clash between the human right to health under the human rights instruments, such as the 
International Covenant on Economic, Social and Cultural Rights, and the intellectual property 
protection offered by the patents under the TRIPS Agreement, has been an issue for the less 
developed and developing countries for quite some time. This was most obvious in the case of 
HIV/AIDS epidemic in the underprivileged countries, where the essential medicines were not 
available because of the patent protection, which impeded the human right to health. 
 
On the one hand, patent protection is necessary. This is because of the fact that patent protection 
is supposed to encourage innovation. If there would be no patent protection, then the companies 
would lose interest to put their efforts in research and development of different life-saving 
drugs. They do this research, because they know, that if they discover something new, then they 
can patent it and through this they gain a monopoly status to sell their original product on the 
market without market competition. 
 
The first chapter of the thesis opens up the essence of the intellectual property. It brings out that 
the Article 27 of the TRIPS Agreement states that there is a patent protection to all fields of 
technology. This means that the inventors can protect their ideas even if it is in the field of 
pharmaceuticals.  
 
The similar protection is provided under the Article 52 (1) of the EPC, which states that 
European patents shall be granted for any invention in all fields of technology, provided that 
they are new, involve an inventive step and are susceptible of industrial application. The 
European Biotechnology Directive goes beyond and creates the presumption that biological 
inventions are patentable subject matter.  
 
TRIPS application in the EU has been somewhat confusing, as it was decided in the CJEU’s 
latest relevant judgment that after the entry into force of the Lisbon Treaty on 1 December 2009, 
the provisions of the TRIPS Agreement fall within the scope of the EU’s common commercial 
policy, which left aside the calm waters laid down by Opinion 1/1994 and its saga. 
 
The importance of patent protection, however, is essential, since as depicted in the first chapter, 
then the research and development costs of producing something new can be quite burdensome 
and the enterprises that deal with innovative ideas expect something in return, which is the 
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monopoly status that the patent protection offers. Without the patent protection, the companies 
would have no choice but to use trade secrets in their doings. However, this would impede 
innovation, since, as it is known, then when one applies for the patent, then one has to reveal 
the patentable product in a manner, that a skilled person could replicate the product if following 
the instructions provided by the applicant. Also, patent procedure is quite a complex and 
somewhat expensive procedure, which means that patents are not handed out randomly. Only 
products that satisfy the conditions of a patent system, for example novelty, can enjoy the 
protection that it offers. 
 
It is considered in the second chapter, on the other hand, that human right to health is an 
important right as well with a moral purpose – so that the society could live its life in dignity. 
Worldwide, this right was first expressed in the Constitution of the World Health Organization, 
which defines health as a state of complete physical, mental and social well-being and not 
merely the absence of disease or infirmity. What is more, it states that the enjoyment of the 
highest attainable standard of health is one of the fundamental rights of every human being 
without distinction of race, religion, political belief, economic or social condition.  
 
Universal Declaration of Human Rights also stated health as part of the right to an adequate 
standard of living. However, as the name suggests, it is a declaration and thus, not binding. But 
Universal Declaration of Human Rights did serve as a basis to produce a treaty that is binding 
on its member states, namely International Covenant on Economic, Social and Cultural Rights, 
which in its Article 12 ICESCR recognises and defines the right to health. Article 12 of the 
Covenant recognises the right of everyone to the enjoyment of the highest attainable standard 
of physical and mental health. "Health" is understood not just as a right to be healthy, but as a 
right to control one's own health and body, and be free from interference such as torture or 
medical experimentation. Article 12.2 requires parties to take specific steps to improve the 
health of their citizens, including reducing infant mortality and improving child health, 
improving environmental and workplace health, preventing, controlling and treating epidemic 
diseases, and creating conditions to ensure equal and timely access to medical services for all. 
These are considered to be "illustrative, non-exhaustive examples", rather than a complete 
statement of parties' obligations. 
 
Also, the European Union recognises the right to health in the Charter of Fundamental Rights 
of the European Union. The Charter brings together the fundamental rights of everyone living 
in the European Union. According to the Charter of Fundamental Rights of the EU everyone 
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has the right of access to preventive health care and the right to benefit from medical treatment 
under the conditions established by national laws and practices. A high level of human health 
protection shall be ensured in the definition and implementation of all Union policies and 
activities. 
 
It is required that medicines must be available, accessible, acceptable and of decent quality. 
Available means that functioning public health and health-care facilities, goods and services, 
as well as programmes, have to be available in sufficient quantity within the State party, 
however, this is connected to the capacity of a State to offer these facilities. Accessible means 
that health facilities, goods and services have to be available to everybody indiscriminately, 
within the authority of the State party. Acceptability means that all health facilities, goods and 
services must be respectful of medical morals and ethnically suitable. Quality indicates that as 
well as being ethnically adequate, health facilities, goods and services must also be 
scientifically and medically fitting and of decent quality. 
 
Since the right to health is included in a number of international human rights treaties, then it 
is first and foremost the states’ obligation to enforce the right to health and human rights 
standards in their respective territory. ICESCR demands states to realise the right to health, but 
it also takes into account the assets of the relevant country. This, however, does not mean that 
the states can sit still and do nothing, they must take reasonable steps in their respective capacity 
to strive in the direction of the full realisation of the right to health. States have three different 
responsibilities, firstly, the responsibility to respect, secondly protect, and lastly, fulfil. 
 
In the third chapter, the means to resolve the conflict that the countries can use, are brought out.  
There is a presumption against conflict in the international law. One way to avoid tension 
between responsibilities is through treaty interpretation.  According to this, norms are 
interpreted in light of another norm to avoid conflict. For example, where TRIPS gives members 
some leeway to determine the exact way how to follow their obligations or where it contains 
unclear terms that need explanation, the right to health may be used in order to notify policy 
choices and to strike a balance between both obligations. 
 
International law prioritises certain interests over others. Nevertheless, there is no proof that 
international law accepts human rights norms, except jus cogens, as higher norms than other 
international law norms. There is no evidence that the whole international community 
60 
 
recognizes the right to health as a peremptory norm. Therefore, lex superior rule cannot be used 
to resolve a conflict between the right to health and patents. 
 
The main way, consequently, in which to evade a conflict between patent law and human right 
to health is in interpreting the TRIPS Agreement in a way which is favourable to endorsing and 
protecting the right to health and access to medicines. 
 
The excellent use of treaty interpretation has been made in India. India, for example, is a country 
that has taken full advantage of the transition period by allowing product patent protection only 
in 2005 upon the expiration of its TRIPS deadline. Until that time, it did not permit product 
patents to be granted to medicines. Accordingly, it was able to develop a sturdy generic 
pharmaceutical industry. Also, India’s definition of “inventive step” is exceptional in that it is 
stricter than in many other countries as it necessitates an invention to include a “technical 
advance”, “economic significance” or both, in addition to the element that the invention is not 
obvious to a person skilled in the art. 
 
A useful tool for balancing access to medicines and patent protection is found in the Article 31 
TRIPS dealing with the compulsory licensing. The use of this measure occurs when a relevant 
body gives its permission for a third party to manufacture the patented product or procedure 
without the permission of the actual patent owner. CL can be used to increase generic 
production, importation and/or domestic competition and therefore lower the medicine prices. 
Compulsory licenses, however, are not handed out easily, since they can limit patent holders 
rights. In cases of national emergencies, nevertheless, compulsory license can be justified. 
 
According to Doha Declaration the signatory states to TRIPS should be able to take the 
necessary steps to ensure the protection of public health and also be able to use the flexibilities 
provided by TRIPS in their full potential. The use of compulsory licenses should not be limited 
to only if there is a national emergency or any other case of great danger. The States should be 
able to decide the conditions that will permit the use of CL. 
 
As compulsory license is a mean to permit for the production and provident to the domestic 
market of the State that issues a compulsory license, then the Doha Declaration did not address 
the problem in connection with the less developed countries with deficient or no engineering 
capability in the medicinal division. This problem was addressed by the 2003 waiver Decision, 
which offered an answer for the unsettled matter and allowed for compulsory license to be 
61 
 
distributed by exporting countries to qualified countries that do not have the necessary 
manufacturing capabilities in the medicinal area. 
 
The answer provided by the 2003 Decision was that the Article 31(f) of the TRIPS was waived 
so that countries that have the capacity to produce medicines could export their inexpensive 
medicinal generic products similar to patented products under compulsory licenses also to the 
less developed and developing countries that have no engineering capability on their own. This 
means that Article 31(f), which hinders the export of medicines, since it only permits to 
distribute medicines inside the country that issued a CL, was cast aside by the 2003 waiver 
Decision to offer an answer to the impoverished countries in order to receive inexpensive 
generic medications that are similar to patented products from capable countries. 
 
The 2003 Decision was also incorporated into the TRIPS Agreement in 2017, when the two 
thirds of WTO members ratified the new provisions. By amending the TRIPS Agreement and 
adding the Article 31bis, the 2003 Decision, which contained the “waiver”, was finally 
integrated with the TRIPS. This was done to address the issue of the fact that the compulsory 
license did not provide any help to countries that have limited capacity to produce essential 
medicines on their own, usually these being less developed and developing countries of the 
WTO. 
 
Article 31bis consists of five paragraphs, which of four are relevant to the study. First one 
allows for the developed countries which contain medical patents to hand out CL for the 
production and exportation of the needed drugs to the qualified countries which have no 
capacity to produce these drugs on their own. The second paragraph deals with compensation 
to the current patent owner and it says that in a case when CL is handed out in the exporting 
State, then the compensation that considers the financial worth to the country the drug is 
exported, should be paid to the patent owner. According to the third paragraph, the 
responsibility under Article 31(f) will not apply for the importing Member, if a developing or 
a less developed WTO Member State is at the same time a part of a local trade treaty. In 
paragraph four it is specified that no challenges should be taken by WTO Member States against 
any measures that will be afterwards taken in conformity with the TRIPS Agreement’s Article 
31bis and its Annex. 
 
In order to integrate the “waiver” from 2003 Decision into the laws of the European Union, 
European Union set up an extensive basis to make sure that the poverty is decreased in 
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connection with prices on different essential medicines. The Regulations adopted belonged to 
the broader action strategy of the European Commission in 2001, which dealt with TB, malaria 
and HIV/AIDS. First regulation is to avoid trade diversion into the EU of certain key medicines 
(Council Regulation (EC) 953/2003), which, in 2016 was repealed and replaced by the 
Regulation 2016/793. This was done because the Regulation 953/2003 had been substantially 
amended several times, so in the interests of clarity and rationality, the Regulation was codified 
by Regulation 2016/793. Since 2016/793 is a codification of the 953/2003, then the essence of 
the initial Regulation remains in force. The other Regulation is on compulsory licensing of 
patent relating to the manufacture of pharmaceutical products for export to countries with public 
health problems (Regulation (EC) No. 816/2006). 
 
For conclusion, it can be said that even if there are tensions between the human right to health 
and the patent law, then the World Trade Organisation and European Union are dealing with 
reducing the conflict between them. This is seen in the various ways that the TRIPS can be 
interpreted and is encouraged to be interpreted by the WTO, as well as the recent amendment 
in the TRIPS Agreement that extend the limits of the compulsory license, so that the products 
could be exported to the countries in need. This is also welcomed in European Union, as the 
EU added two relevant Regulations to its legislation to accept the changes made in TRIPS 
Agreement in connection with the compulsory license. It is, however, still troubling that the 
various means to resolve the clash has not been used as much as desired. The reason could be 
that the system is still perhaps too complex and time-consuming or that the countries that have 
health issues are not competent enough to effectively take use of these measures. 
 
 
 
 
 
 
 
 
 
 
 
  
63 
 
Abbreviations 
 
CESCR Committee on Economic, Social and Cultural Rights   
CJEU  Court of Justice of the European Union 
CL  Compulsory License 
EC  European Commission 
EP  European Parliament 
EPC  European Patent Convention 
EPO  European Patent Office 
EU  European Union 
GATS  General Agreement on Trade in Services 
GATT  General Agreement on Tariffs and Trade 
GSK  GlaxoSmithKline 
HIV/AIDS Human immunodeficiency virus infection/acquired immunodeficiency 
syndrome 
ICESCR International Covenant on Economic, Social and Cultural Rights 
IP  Intellectual Property 
IPR  Intellectual Property Right 
LDC  Least Developed Countries 
OECD  Organization for Economic Co-operation and Development 
R&D  Research and Development 
SME  Small and Medium-sized Enterprises 
TB  Tuberculosis 
TEU  Treaty on European Union 
TFEU  Treaty on the Functioning of the European Union 
TRIPS  Agreement on Trade Related Aspects of Intellectual Property Rights 
UDHR  Universal Declaration on Human Rights 
UN  United Nations 
VCLT  Vienna Convention on the Law of the Treaties 
WTO  World Trade Organization 
WTO  World Trade Organization 
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